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Abstract
THE ISOLATION AND CHARACTERIZATION OF GROWTH REGULATORY FACTORS PRODUCED
BY A HERPES SIMPLEX VIRUS TYPE 2 TRANSFORMED MOUSE TUMOR CELL LINE, H238

by
Robert B. Stagg

Transformation

of

cells

with

herpes

simplex

virus

Type

2

(HSV-

2)occurs by an unknown mechanism. No specific gene or gene product has
been consistently associated with HSV-2 transformation as is the case
This study was performed in an attempt to

for other tumor viruses.

associate HSV-2-transformation with specific growth factors in order to
develop a

testable model

For

for HSV-2-transformation.

viruses, particularly those containing RNA,

some

tumor

there has been a central

concept (autocrine secretion) linking oncogenes and growth factors. This
concept centers

on the

ability of

the cancer

cells

to produce

and

We report here the isolation

respond to their own autologous factors.

and characterization of four growth regulatory factors produced by H238,
an HSV-2-transformed mouse tumor cell line.
The H238 cells were grown in culture flasks to two-thirds confluency
in medium containing 10% fetal bovine serum. The medium was removed, the
cells were washed and medium without serum was added to the cells. At
intervals

of

48

contained

growth

this

hours,

regulatory

withdrawn and stored frozen.

conditioned
factors,

medium

produced

These factors were

(H238-CM),

by

the

which

cells,

was

separated from the

H238-CM by heparin-sepharose affinity chromatography into three peaks of
mitogenic

activity

and

a

fourth

containing

inhibitory

activity

for

splenocytes.
based

on

The three peaks of mitogenic activity have been identified

physiochemical

characteristics:

the

first

supported

the

anchorage-independent growth of EGF treated NRK-c-49 cells and resembles
transforming growth factor-^ (TGF-/3); the second bound to lectin-coated
sepharose beads and was sensitive to trypsin, neuroaminidase, and the
resembled a platelet-derived

reducing agent dithiothreitol (DTT) and,

growth factor (PDGF)-like factor; and the third displaced [ 125I]-labeled
basic fibroblast growth factor (bFGF) in a dose dependent fashion when
tested with a radioimmune assay (RIA).
for a variety of splenocyte
induced blastogenesis,

expression.

function assays.

It

inhibited lectin-

allogenic mixed lymphocyte reaction (MLR),

IL-2 production by splenocytes.
transition causing

The fourth peak was inhibitory

and

It appeared to act on splenocyte Gq/G-^

growth arrest by

inhibiting

c-myc

proto-oncogene

A model for the interaction of these factors in vivo is

presented with an emphasis on testability.
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The Isolation and Characterization of Growth Regulatory Factors Produced
by a Herpes Simplex Virus Type 2 Transformed Mouse Tumor Cell Line, H238

Introduction

The H238 tumor cell line (1)

is an embryonic fibroblast of BALB/c

mouse origin transformed in vitro by infection with ultraviolet light
(UV)-irradiated herpes

simplex virus

Type-2

(strain

Savage;

HSV-2).

Oncogenic potential of the cell line has been established in many doseresponse experiments (1,2).
1 x 10

£

A 100% incidence of tumors is produced when

cells are injected subcutaneously into syngeneic hosts.

studied the host's

response

modification of this

to

response

the
(2-5).

tumor challenge
During these

and the

We have
dietary

studies we have

observed specific instances where the tumor cell apparently affects its
own ability
factors.

to

form

tumors by

the production

of growth

regulatory

The in vitro inhibition of spleen cell proliferation (6) and

colony formation in soft agar (1 and unpublished observation in our
laboratory)

and in vivo angiogenesis

laboratory)

are H238

(unpublished observation in our

tumor characteristics believed to be under

control of growth regulatory factors.

the

In experiments described in this

dissertation we have looked at the growth regulatory factors produced in
vitro by the tumor cells and have attempted to establish a testable
model of HSV transformation and tumor induction.

1

2
Transformation by HSV is an exception to normal tumor virus action.
Tumor viruses

found among both DNA-

and RNA-containing viruses

All RNA tumor viruses belong to the retrovirus group in which

(7,8).
the

are

viruses

are

polymerase

which

characterized
functions

in

into

reproduction
retroviruses

a host
of

cell

these

contain

containing

producing

a

an

RNA-dependent

DNA
(DS)

double-stranded

This DNA molecule is circularized and

complement of the RNA genome.
inserted

as

chromosome

as

(v-onc),

necessary

part

All

of

the

which

are

believed

retroviruses.

oncogenes

a

of

the

transforming
to

have

originated from cellular proto-oncogenes by inappropriate recombination
(8,9).

These oncogenes are required for the induction and maintenance

of the transformed state.
All of the groups of DS DNA-containing viruses contain members with
demonstrated oncogenic potential (7,10).

In the papovavirus group,

which the DS DNA is circular, all of the members are oncogenic.
least one case, that of the simian virus SV-40

in

In at

the entire viral genome

is integrated into a host cell chromosome as is evidenced by the fact
that the virus can be "rescued'’ from the transformed cells by fusing
them with permissive non-transformed cells.

In cells transformed by a

number of other DS DNA-containing viruses, only a portion of the viral
genome

is

integrated

integrated
genomic

as

shown by hybridization

fragments

have

been

shown

in

techniques.
some

These

instances

to

contain specific genes which are necessary for induction and maintenance
of the transformed state.
For the HSV no specific gene or gene product has been consistently
associated with transformation

and in several reports (11-13) no stable
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HSV genetic material has been demonstrated after continued passage of
This lack of stability has proven to be a difficult problem

the cells.

in the elucidation of the mechanism of HSV-induced transformation.
In spite

of these

observations

HSV

is

still

believed

to

induce

transformation by an alteration in the genetic make-up of the cell.
This

alteration

allows

the

transformed

to

escape

For normal

controlled cell proliferation cycle.
growth factors

cell

cells,

the

polypeptide

acting in a carefully orchestrated fashion

their proliferation (14-16).

tightly

stimulate

Growth factors exert their control of cell

proliferation by binding to specific receptors expressed on the cellular
membrane (15) .

The cells activated by these growth factors share a

common phenotype with transformed cells and appear to activate the same
metabolic pathways (16).

Because of these similarities, one of the more

plausible explanations for oncogenic transformation is the deregulation
of the cell cycle by mimicking growth factors and/or their receptors.
This, in fact, has been demonstrated for RNA tumor viruses where several
oncogene products share homology with growth factor receptors, and one,
the simian sarcoma virus oncogene v-sis, shares homology with the gene
for the

chain of platelet-derived growth factor (17).

DNA tumor virus

oncogenes do not share homology with cellular genes but appear to act by
affecting the regulation of the cellular homologs of the oncogenes, the
proto-oncogenes (10,18,19).
where no
(20,21).

specific gene
In

an

This does not appear to be the case for HSV

transcript

attempt

to

is

involved

determine

in

possible

this

deregulation

routes

of

HSV

deregulation, genetic alterations, we have looked at the growth factors

4
produced by

the

transformed

cell as

a possible

mechanism for

this

transformation.
In the succeeding pages we will first review information pertinent to
the dissertation,

specifically HSV tr-ansformation,

growth factors and

spleen cell growth inhibitors, followed by two papers characterizing the
growth regulatory factors produced by the H238 tumor cell line,

and

finally a discussion of a proposed model for the interactions of these
factors in tumor formation.

HSV Transformation

HSV

became

a

tumor

virus

candidate

through

the

epidemiological

studies of Rawls (22) and Nahmias (23) .

They observed a statistically

significant

cervical

presence

of

association

in

women

serum antibodies

etiology of a human tumor.

with

to HSV,

carcinoma

implicating the

with

virus

in

the
the

Duff and Rapp (24,25) provided the first

direct evidence for the transforming potential of HSV.

A UV-irradiated

HSV was employed to transform in vitro cultured hamster fibroblasts.

In

order to eliminate the reproductive capacity of the HSV, the virus was
UV-irradiated,

damaging the viral DNA and blocking action of the DNA

transcriptase.

The inactivated virus was capable of infecting the host

cells and contained essentially a full complement of genes
potential viral oncogenes.

including

This demonstration set in motion a search

for the molecular mechanism by which HSVs induced transformation.
Since that first report HSV has been used to transform a wide variety
of cells.

Mouse (1,26,27), rat (20,28), and human lung and embryonic

5
cells (29) have been transformed using HSVs that have been inactivated
by

a

variety

of

means:

(1,24,26,30),

UV-irradiation

temperature

sensitive mutants (31,32), photodynamic inactivation (24,26,30), sheared
most recently, restriction enzyme-cut viral DNA

DNA fragments (33), and
fragments (20,31,34-38).

The search for viral-coded mRNA in transformed cells

(39-42)

was

successful but transcripts representing only 5 to 13% of the HSV genome
were

This

detected.

observation pointed

out

the

possibility

that

incorporation of the entire viral genome was not necessary to transform
Frenkel

cells.

and

associates

(43)

demonstrated

viral

genome

They detected the presence

incorporation using DNA:DNA hybridization.

of HSV DNA in the transformed cell after cloning the transformed cells
but observed that as in vitro passage history increased, and/or passage
through an animal host,
The

decreased.

the amount of viral DNA present in the cell

transformed

cell

apparently

only

retained

those

sequences necessary for maintaining the transformed state.
Several

laboratories

began

to

look

for

specific

transforming

sequences using defined fragments of HSV DNA produced by restriction
enzyme cleavage of the HSV genome (20,31,34-38).

With these fragments

one region of the HSV-1 (20,35) and two regions of the HSV-2 genomes
(20,36,37) were found to induce transformation.

Significantly, neither

of the two HSV-2 transforming regions showed any sequence similarity to
the HSV-1 region (20).
0.31

and

0.42

glycoprotein

map

leading

transformation.

The HSV-1 transforming region, mapping between

units
to

(MU),

was

speculation

found
of

to

its

code

for

possible

a

membrane

function

in

6
Two HSV-2 transforming regions have been reported from laboratories
employing different selection criteria,

one mapping between 0.56

Galloway and

0.63 MU (20) and the other between 0.48 and 0.58 MU (37).
McDougall

(36)

attempted

reports to determine
genome

with

fragments

to

unify

the

data

from

several

if there really were two regions

transforming

into plasmids

They

potential.

cloned

and amplified them for

and

different

of the HSV-2

the

restriction

easier manipulation.

Their study indicated a single region of the HSV-2

genome,

mapping

between 0.58 and 0.63 MU, that was capable of altering the morphological
phenotype of murine tissue culture cells and was tumorigenic in newborn
and nude mice.

Subsequently, they found that this region did not encode

a complete protein (21),

making comparison to an oncogene difficult.

Further, they could find a copy number of only 0.1 copies per cell of
the HSV-transforming region (36).
Implied in the early work on HSV transformation was the idea that
transformation

involved

the

stable

incorporation

material and its expression in the transformed cell.
Galloway and McDougall

(36)

this

became

a

of

viral

genetic

With the report of

questionable

hypothesis.

First Skinner (11), then Galloway and McDougall (12), and later Cameron
and

associates

mechanism

of

(13)
HSV

insensitive assay
associates

proposed

a

"Hit

and

Run"

Skinner,

transformation.

hypothesis
using

a

for

the

relatively

was unable to repeat the earlier work of Frenkel and

demonstrating

viral

DNA

in

the

transformed

cells.

He

proposed a model of transformation where debilitated HSV initiated the
transformation but was discarded by the newly transformed cell during
mitosis because it was not integrated into the cell's DNA.

7
With

this

model

in mind several

laboratories began

to

look

for

activation, by a "Hit and Run" HSV, of endogenous retrovirus (30,44-46),
(this virus family contains the RNA tumor viruses) the theory being that
these activated retroviruses were the etiological agents that induced
and maintained

the

transformed

retroviral activation was

The

state.

search

demonstrated in several

transformed by debilitated HSV.

was

successful;

rodent cell

lines

But recently Duesberg (47) has argued

persuasively that only mutated retroviruses containing oncogenes

are

able to transform, clouding the significance of the above observations.
Subsequent

to

Frenkel

and associates'

reporting

(43)

stable

HSV

genetic material in the HSV-transformed cells other laboratories have
been able to reproduce these results with other HSV-transformed cell
lines.

Reyes and coworkers (20) demonstrated the stable incorporation

of the HSV-2 restriction fragment, 0.58-0.63 MU,
cells.

Galloway and McDougall

(36),

into the transformed

utilizing the same restriction

fragment, demonstrated similar results with low copy number per cell.
But after passage through an animal host the in vivo tumor cells had an
increased copy number of viral DNA per cell suggesting selection for
viral DNA-containing cells to maintain oncogenicity.
Currently Galloway

and

associates

(21)

have

dissected

the

HSV-2

restriction fragment, 0.58-0.63 MU, and reported a 737 base-pair segment
that has insertion sequence-like structures.

They propose an insertion

promotion mechanism for transformation similar to that reported with
some other retroviruses.

This has yet to be demonstrated but could

account

of

for

deregulation

growth

factors.

No

reports

have

yet

8
appeared in the literature that develop the relationship between HSVinduced transformation and specific growth factors.

The H238 Tumor System

The H238 tumor cell line in this study was originally
cells

transformed

embryonic

in vitro by

fibroblast

cell

infecting

line,

with

238

cells,

UV-inactivated

vivo at inoculums of 1 x 10^ cells.

HSV-2

mouse
(strain

Debilitation of the HSV-2 was

accomplished by eight minutes of UV-irradiation.
was

a BALB/c

The parental 238 cells are not able to produce tumors in

Savage) (1).

cells

derived from

induced

by

infection

with

the

multiplicity of infection equal to one.

Transformation of 238

debilitated

virus

at

a

Putatively transformed H238

cells were selected from foci after continued passages of infected cells
on

the

basis

of

altered

colony

The

morphology.

selected

cells

demonstrated loss of both contact inhibition and an ability to grow in
soft agar, characteristics of transformed cells.

The presence of HSV-2

proteins could be demonstrated in the original clones of transformed
cells by cytofluorometric analysis but attempts to recover infectious
virus have been unsuccessful.
not been

able

to

After passage in our laboratory we have

find expression

of the

HSV-2 proteins

previously

reported (unpublished observation by Dr. Kettering).
The oncogenic potential of the newly transformed H238 cell line was
evaluated and established by subcutaneous inoculation of the cells into'
the syngeneic BALB/c host.

The tumors produced are invasive sarcomas,

not otherwise differentiated, in the soft tissue of host animals.

They

9
are well vascularized with enlarged lymph nodes in the proximal area,
and metastasis occurs, most frequently to the lungs (2).
Our previous work has detailed dietary modifications that alter host
BALB/c mouse response to H238 tumor challenge (2-5).

We have compared

the effects of tumor challenge on mice fed various amounts and sources
of carbohydrate, protein and lipids.
tumor

incidence,

tumor volume,

We have observed differences in

relative

spleen weight,

spleen

cell

differential counts, cell-mediated immunity, and decreasing lymphocyte
blastogenesis with increasing spleen weight and tumor volume (3,4).
spleens

of

tumor bearing mice

tissue,

lymphoid nodule

show

reactive

an increase

centers,

in compact

The

myeloid

and red pulp volume

(2).

Further, we have shown that the inhibition in lymphocyte blastogenesis
is mediated by cells of macrophage phenotype whose presence is required
for the inhibition to occur (5).

Growth Factors

Growth factors are technically defined as polypeptides that produce
their physiological effects by binding to specific receptors present on
the target cell's membrane (14-16).

Unlike classical hormones they are

produced and act locally after a short diffusion (14-16).

The receptor-

growth factor interaction initiates a chain of cytoplasmic and nuclear
events that culminates in the initiation of DNA synthesis.

The ongoing

discovery and elucidation of these events and their consequences remains
an important challenge of molecular biology.

10
Originally, growth factors from other sources were isolated on the
basis of their ability to induce proliferation in tissue culture cells.
Currently, the observed effects of growth regulatory factors encompasses
a wider

spectrum

of

activities,

from

proliferation

and

inhibition

For example one

effects to the induction of differentiated states.

growth factor, transforming growth factor p (TGF-/?), first characterized
by its ability to
cultures,

is

support anchorage-independent growth in soft agar

now believed

to

be

a bifunctional

regulator

inducing

proliferation in some cell types while inhibiting other types (48,49).
While other growth factors, such as interleukin-1 (IL-1), first thought
to be

tissue

specific,

have been

found upon

closer examination

to

produce physiological effects in several cell types (50,51).
The demonstration of the bifunctional nature of TGF-/3 has renewed
interest in the study of factors that maintain cell homeostasis.

The

study of these negative regulatory factors has a long history but they
Chalones,

have not received as much recent attention as growth factors.
as

inhibitory factors were originally designated,

difficult to isolate and characterize (52).
(IFN)

are

involved

the best studied examples
in

maintaining

the

have proven to be

TGF-/3 and the interferons

of inhibitory factors

delicate

balance

between

that are

growth

and

quiescence (53,54).
The identification of polypeptide growth regulators arose from the
observation that serum, an additive to tissue culture medium, contained
factors necessary for in vitro cell growth and multiplication.
this intuitive knowledge,
proliferation

assays

and

several laboratories
applied

biochemical

(55-58)

With

developed cell

protein

purification

11
Leof

techniques to isolate and characterize specific growth factors.
and

associates

(59),

using

a

fibroblast

proliferation

model,

demonstrated that an orchestrated interaction of three growth factors
was necessary for quiescent cells to initiate and then complete the cell
cycle.

They proposed

a competence

and progression model

(59)

for

fibroblasts that corresponded to classically described Gq/G-^ transition
and late G-^/S progression,

respectively

platelet-derived growth factor (PDGF)

(60) .

For the

fibroblasts,

induces a competent state while

progression is regulated by epidermal growth factor (EGF) priming and
subsequent driving to completion by insulin-like growth factors (IGF).
The competence and progression hypothesis also holds

true for other

proliferation models, for example the lymphocyte model where antigen and
IL-1 regulate competence and IL-2 controls progression (61,62).

This

will be discussed in a succeeding paragraph.
Concurrently

it

was

noted by

others

(63,64),

that

tumors

cells

characteristically required less exogenous serum for in vitro growth.
Applying similar isolation methods it was discovered that transformed
cells produce endogenous growth factors that appear to affect their own
proliferation.

These observations led Sporn and Todaro (65) to propose

an autocrine and paracrine hypothesis by which the transformed tumor
cell could maintain itself and gain an advantage over normal tissue.
Autocrine stimulation is defined as the production of growth factors by
the tumor cells bearing receptors for the factor.

Paracrine stimulation

involves the production of growth factors by the tumor cells that affect
the surrounding tissues causing them to interact with the tumor in a
beneficial way,

producing factors necessary for tumor growth and the

12
migration of tissues required by the growing tumor,

one example being

angiogenesis.
Another

intriguing development,

observation

of

a

relationship

that

is

between

still unfolding,

growth

factors

and

was

the

oncogene

products (66,67) and that growth factors could regulate the expression
of

proto-oncogenes

normal

cellular

homologues

of

the

Two growth factor genes have been identified as transforming

oncogenes.
genes:

the

(68-71)

the v-sis oncogene of simian sarcoma virus has

1)

extensive

homology to the /?-chain gene of PDGF (17), and 2) the int-2 gene, having
homology to the fibroblastic growth factor gene, has been reported to be
The v-erb-B (73) and v-

the transforming gene of Kaposi's sarcoma (72).

fms (74) oncogenes appear to share homology with the genes of the EGF
and

colony

stimulating

factor-1

(CSF-1)

receptors,

respectively.

Further, growth factors have been shown to regulate the expression of
nuclear proto-oncogenes c-fos

c-myc (68,69) ,

(69,70)

which in turn correlate to cell cycle progression,

and c-myb

(71)

c-fos and c-myc

expression occur during Gq/G-^ transition and are induced by competence
factors such as PDGF and interleukin-1 (IL-1) (75-77).

c-myb expression

occurs during the late G-^/S phase of the cell cycle and has been linked
to interleukin-2 activation of the lymphocyte model (78,79).
provided

the

transformation

scientific

community

with

a

testable

This has
model

for

and a plausible explanation for the relaxed control of

the cell cycle seen in transformed cells.
A short review of the biochemical and physiological characteristics
of

several

well-defined

growth

regulatory

factors

follows.
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Proliferation factors are reviewed first,

followed by descriptions of

inhibitory factors.

Growth Regulatory Factors

Platelet-derived growth factor (PDGF) is the major mitogen of serum
(80,81).

This heterodimer glycoprotein has a molecular mass of 30-32

kilodaltons (kDa) that is made up of a 14-18 kDa a chain and a 16 kDa
First purified from human platelets, it has now been shown to be

chain.

produced by

placenta,

endothelial

cells,

aortic

smooth muscle,

and

tumors of mesenchymal origin which synthesize a p-f3 chain homodimer.
Receptors have been demonstrated on a variety of mesenchymal cells,
placenta trophoblasts, and fibroblasts.
receptors per cell.

The latter have about 400,000

The c-sis proto-oncogene codes for the p chain

while the v-sis oncogene

is the transforming gene of simian sarcoma

Besides being a potent competence factor for fibroblasts,

virus (17).

PDGF elicits a chemotactic response in fibroblasts and smooth muscle
(82) and is believed to be an important component of the wound healing
process (83).
Epidermal growth factor (EGF)
(84).

is a 6 kDa single chain polypeptide

It is mitogenic for a variety of mesenchymal and epithelial cells

and induces aspects of differentiation in certain cell types.
important component of tooth eruption (85) .

It is an

EGF effects are potentiated

by insulin and EGF acts synergistically with PDGF in fibroblasts (59) .
Expression of the EGF gene has been observed in a wide variety of
tissues.

To the present

time no tumor cells have been found that
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produce EGF, but several produce a similar molecule, TGF-a (see below),
that binds to the EGF receptor (86,87).
embryonic form of EGF.

TGF-a is believed to be an

The v-erb-B oncogene, the transforming gene of

the avian erythroblastosis virus, is homologous to the EGF receptor gene
except that the EGF binding region is deleted in the oncogene product
(73).

EGF is reported to regulate its own receptor expression (88) .

EGF binding causes an initial disappearance of the receptor from the
membrane, but binding increases the transcription of the receptor gene.
Insulin-like growth factors (IGF) are a family of 7 kDa peptides that
are

insulin-like

in

amino

acid

mesenchymal and epithelial cells

sequence

and
IGF-1

(89) .

act

on

a

variety

somatomedin C,

of

is an

important component of serum and plasma having mitogenic activity in a
The

large number of cell types and has been isolated from tumor cells.

IGF-1 receptor gene is similar to the family of c-src proto-oncogene
•rv>'

tyrosine kinases with the f) chain of the receptor sharing sequence
similarity with the c-ros proto-oncogene.

v
k

The mitogenic activity of

insulin itself has been shown to be mediated through the IGF-1 receptor
(90).

The

role

of

IGF-2

in

the

proliferation

process

is

more

controversial with reports ranging from no activity (91) to action as a
mitogen (92) and/or the regulation of calcium influx (93) .

IGF-2 has

now been identified as the skeletal growth factor described by Baylink
and associates (94).

The IGF-2 receptor has recently been cloned and

shown to be a bifunctional receptor (95,96).

Besides binding IGF-2 it

also binds mannose-6-phosphate which is believed to be
intracellular lysosomal enzyme trafficking (97).

important

in
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Members of the interleukin (IL) family of growth factors are related
by their ability to stimulate the proliferation of lymphocytes and other
IL-1 is a 12-16 kDa single chain peptide that is a

hematopoietic cells.

potent competence factor for lymphocytes (61,76).
an

integral

macrophages.

component

of

antigen

presentation

It is believed to be
to

lymphocytes

by

IL-1 induces the production of other hematopoietic growth

factors, colony stimulating factors (see below), in fibroblasts (50) and
vascular endothelial cells (98), and to be an agent of inflammation (99)
and chemotaxis (100).

IL-2, the major mitogen of the T-lymphocyte, is a
Lymphocytes must first be activated by

15 kDa glycoprotein (62,101).

IL-1 and antigen before receptors for IL-2 appear on the plasma membrane
Antigenic

(102).

challenge

induces

the production of IL-2

and the

expression of IL-2 receptors on lymphocytes; this is an example of the
autocrine hypothesis working in normal

tissues.

IL-2

can also up-

regulate its receptor expression after an initial down-regulation of the
IL-2 receptor complex (69,102).
Colony-stimulating

factors

regulate

(CSF)

differentiation of hematopoietic precursor cells
glycoproteins have been described.
CSF-2,

the

growth

(103,104).

and

Several

They are: CSF-1, a 70 kDa homodimer,

a 15-28 kDa single chain protein,

multi-CSF (IL-3),

a 28 kDa

single chain polypeptide believed to be the stem cell growth factor,
granulocyte-CSF,
factor),

a

24.5

kDa protein,

and

differentiation

factor

(D

a 62 kDa protein apparently identical to another previously

described factor, MGI-2.
proto-oncogene (74).

The CSF-1 receptor is encoded by the c-fms
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Fibroblastic

growth

factors

(FGF),

also

referred

to

as

heparin

binding growth factors, are 14-18 kDa single chain proteins that have
slight sequence similarity to IL-1 (105,106).
cells

derived

from

embryonic

mesoderm

and

They are mitogenic for
cultured

neuroectoderm

fibroblasts, and vascular endothelial cells and induce angiogenesis in
vivo (107).

Cells that are sensitive to the proliferative action of FGF

have about 20,000-40,000 receptors per cell.

The FGF gene has been

implicated in the transformation of Kaposi's sarcoma cells (72), found
in patients suffering from acquired-immune deficiency syndrome (AIDS).
The int-2 transforming gene of Kaposi's sarcoma is homologous to the FGF
gene.
in

the

Recently FGF has been reported to act synergistically with TGF-/9
induction

of

mesoderm

formation

during

amphibian

embryonic

development (108).
Transforming growth

factors

(TGF)

derived

their

name

from

their

ability to stimulate the anchorage-independent growth of normal cells, a
characteristic usually associated with tumor cells

(63,109).

Several

types have been described but the most studied are TGF-a and TGF-/3.
TGF-a is a 5.6 kDa single chain protein that has sequence similarity
with EGF (87).

Its effectiveness on a molar basis equals that of EGF in

most systems.

TGF-/? is a 25 kDa homodimer polypeptide that is capable
It supports anchorage-independent

of bifunctional regulation (48,49).
growth of suspension cultures while
monolayer

cultures.

Inhibition

by

inhibiting the proliferation of
TGF-/?,

in

some

cell

lines

of

epithelial origin, is achieved by the down-regulation of high affinity
EGF receptor expression (110).

TGF-/? has been reported to induce in

vivo angiogenesis (107), chemotaxis of monocytes and macrophages (111) ,
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lymphocyte inhibition (99), differentiation of various tissues, and the
induction

of

PDGF

synthesis

in

fibroblast

cultures

It

(112).

is

biosynthesized in an inactive form by most tissues and tumor cells and
must be

activated by

Current -theory

acidification.

regarding

its

inability to inhibit tumor cells centers on the observation that tumor
cells have lost their ability to respond to the factor in a normal
fashion (113).

Receptors, about 10,000-40,000 receptors per cell, for

TGF-/? have been found in all tissues tested.
Interferons (IFN) are potent inhibitors of cell proliferation that
will also stimulate the cell-mediated immune response (54).
have been identified, a, (3, and 7.

Three types

Originally IFN were described for

their antiviral actions but now have been shown to inhibit proliferation
in a

number

of normal

and

transformed cells.

They

inhibit

Gq/G-^

transition by interfering with the establishment of competence and the
expression of competence genes (114,115).

IFN /3, a 20 kDa protein, is

identical to a B-lymphocyte differentiation factor (116).
Several other negative growth regulatory factors have been described.
Among these are:

fibroblast growth regulator,

a 13 kDa single chain

protein that inhibits fibroblast proliferation (117), inhibin, a 32 kDa
heterodimer related to TGF-/J that regulates follicle-stimulating hormone
secretion by the pituitary (118), and several tumor cell proteins (119121) in the 13 kDa range that inhibit lymphocyte proliferation.
of the similarities in molecular mass,
proteins and dimer subunits,

Because

12-13 kDa, of the single chain

it has been suggested that these factors

may represent a family of proteins involved with the negative regulation
of cell growth (122).
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Tumor-Derived Inhibitory Factors

A large body of literature exists regarding the inhibitory effect of
tumor cells

on the normal cell proliferation of the

immune

system.

Interest in this area, the direct effects of tumor cell products on the
positive effector cells of the immune system, has declined with the
discovery of an immune self-regulatory mechanism (T-suppressor cells)
Immune suppression is now believed to be mediated through

(123-125).
this

suppressor

system

(126,127).

Tumor

cells

could

stimulate

simultaneously the suppressor cells and the positive effector cells (Thelper and/or -cytotoxic cells), thus inhibiting the positive response
without the need of specific suppressor products.
demonstrated

that

positive

effector

cells

Recently it has been

(T-cytotoxic)

could

be

isolated from growing tumors and expanded in number in tissue culture
under the control of an immune cell growth factor
(128).

interleukin-2 (IL-2)

When these cells were reintroduced intravenously,

inactivation of the T-suppressor cells,
increased,

along with

the life span of the animals

and in some cases even eradication of the tumor occurred.

Even if the suppressor system were an important component in the control
of the positive effectors, the presence of activated T-cytotoxic cells
in the locale of the tumor and their inability to inhibit tumor growth
again raises the question of what direct effect the tumor may exert over
the normal actions of the immune cells.
A variety of immunosuppressive agents isolated in vitro from either
fluids of tumor-bearing subjects or from the tumors themselves have been
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reported .

These range from plasma and ascites fluids to solublized

tumor cell extracts.
The observed immunosuppression in cancer patients led researchers to
look for tumor-produced immunosuppressive agents in the serum and plasma
of human subjects (129-133) and human cell lines and animal models (119121,134-141).

Several

components

of

serum

and/or

plasma

of

tumor

bearing subjects were found to inhibit the immune response.

a-Globulin

(130),

low-density

(129),

a-glycoprotein

lipoproteins (132),

a-fetoprotein

(131),

and prostaglandins (133) were shown to inhibit in

vitro spleen cell proliferation assays.
these components were tumor-specific.

It was determined that none of
They were found also in normal

serum and/or plasma (142,143) and were probably not responsible for the
observed in vivo immunosuppression.

The isolation of immunosuppressive

proteins produced by the suppressor lymphocytes (144-146) in response to
tumor burden cast further doubt on the validity of the interpretation of
the previously demonstrated immunosuppressive agents.

Recently this has

come full circle with the demonstration of a difference in the nuclear
magnetic resonance profiles of the plasma low-density lipoproteins of
normal and tumor bearing subjects by Fossel and associates (147).
Direct inhibition of immunological assays by tumor cells and/or their
products has been demonstrated for a variety of tumors
141) .

Inhibition

of

lymphoproliferation

(119-121,134-

(119-121,134,138),

IL-2

production (119,121,134), antibody response (135), cytotoxic lymphocyte
development (119), and macrophage function (136) by tumor cell culture
supernatants are well documented.

Extracts and culture supernatants of

melanoma tumor cells have been shown to inhibit lectin-induced spleen
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cell proliferation and IL-2 production (137,148).

Mastocytoma products

inhibit mitogen-induced spleen cell proliferation and allogenic mixed
lymphocyte cultures (138,149).

Cellular products of human tumors of the

colon (121,150) and esophagus (139), human leukemias (140), and human
tumor ascites

fluid

(141,151)

inhibit in vitro

immunological

The isolation

designed to evaluate the competence of the immune system.
that inhibit similar in vitro

of normal cell products

assays

immunological

assays (152-154) has demonstrated the need for careful evaluation of the
Inhibition of spleen cell proliferation by the

isolated molecules.

artificial concentration of histones (152,153) and arginase (154), found
in

the

Further,

supernatants
some

of

normal

cell

cultures,

inhibitors of immunological assays

has

been

reported.

isolated from tumor

cell culture supernatants have been shown to be intact viruses (155) and
retroviral proteins (156,157).
Immunologists, in general, began to feel that these are all normal
cellular products that could inhibit in vitro spleen cell proliferative
They reasoned that the in vitro inhibition probably would

assays (158) .

not be reflected in the in vivo system.
emerging knowledge of the

This idea coupled with the then

immune system's

self-regulation,

with

its

positive and negative effectors (123-125), led to a decreased interest
in tumor product inhibition of the immune response.
Several
position.

recent
1)

observations

Rosenberg

and

compel

associates

infiltrating lymphocytes (TIL) and
adoptive

immunotherapy;

a partial

the TILs

(128)

rethinking
have

of

isolated

this
tumor

demonstrated their effectiveness in
appear

to be

fully sensitized but

require in vitro clonal expansion with IL-2 before they have therapeutic
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2) Lau and coworkers (159) have demonstrated the successful

benefit.
use

and

superior

therapeutic

action

biological response modifiers

(BRM)

Japanese

observed

immune

investigators
response

to

have

inactivated

of

intralesionally-administered

in controlling tumor growth.
a

lymphoma

site-specific
cells

in

3)

cell-mediated

animals

bearing

progressive tumors of the same origin and have suggested that immature
cytotoxic

T-lymphocytes

(CTL)

migrate

to

the

tumor

site

and

there

develop into mature CTLs (160).
The existence of the suppressor T-cells and their importance in the
control

of

necessity

the
for

positive
the

successful adoptive
(128,161,162).

effector

elimination

cells

of

these

is

not

in

question.

T-suppressor

cells

The
before

immunotherapy can occur has been well-documented

Rosenberg and associates (128) found that administration

of cyclophosphamide

(Cy),

a potent anti-T-suppressor

cell

agent,

in

combination with TILs was necessary for therapeutic benefit to occur.
But they demonstrated,

as

others before

(161,162),

effect on tumor burden or life span when Cy was
combination with

IL-2.

What makes

the

TIL

only

a marginal

given alone or

adoptive

in

immunotherapy

procedure unique is the possible utilization of the animal's own immune
cells and its application to human therapy.

The fact that a small

number of sensitized effector cells could be demonstrated at the tumor
site and that these cells were not therapeutically effective within the
animal, even when suppressor activity was eliminated by Cy treatment,
points to the possible role of tumor products in the inhibition of the
in vivo immune response.

Also, the finding that these cells were viable

and capable of in vitro clonal expansion,

in the presence of growth
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factors (IL-2) at therapeutic levels, may indicate a possible mode of
action for the tumor products.
Lau and

coworkers

(159)

have

demonstrated

recently

the

superior

therapeutic effect of interlesional immunotherapy with immune modulators
C.

parvum

enhance

and A.

the

The use

sativum.

existing

immune

of

response

immunological modulators
owes

its

foundation

to

to

the

observation that some cancer patients have had miraculous recovery from
It is difficult to

their tumors following a serious infectious disease.

assume that interlesional immunotherapy with C. parvum could eliminate
the local suppressor T-cell's activity as its mechanism of action for
A more realistic mode of action would involve

the potentiation of CTLs.
the

local

positive

recruitment
immune

of

response

all
and

the

accessory

a local

cells

increase

in

necessary
the

IL-2

for

a

levels,

allowing the CTLs to escape suppression and perform their task.
Fuyama and his associates

(160) have demonstrated the ability of

mice, bearing a progressive radiation-induced lymphoma (RL 1) on their
backs,

to

induce a detectable CTL response to radiation-killed RL 1

cells introduced into their peritoneal cavities.

This is a somewhat
They

startling observation in light of the suppressor T-cell model.
hypothesize the maturation of immature CTLs at the tumor site.
and

associates

(161)

have

isolated

an

IL-2

inhibitor

suppressor T cells and theorized a mechanism for the
nonspecific

activity

of

presence

of high levels

possibly

limit

the

IL-2

of IL-2

activity

producer cell in vivo.

in

of

a

specific

inhibitor
IL-2

to

immune

in the

the

close

Hardt

produced

by

control of the
The

response.
animal

serum may

vicinity

of

the

These two theories are not mutually exclusive
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and would fit well into the model of local inhibition of the immune
response by tumor products.
tumor site but the

The immature CTLs could migrate to the

tumor factors would inhibit their maturation and

clonal expansion.

Lymphocyte Proliferation Model

The

discovery

of

T-cell

growth

factor

IL-2

(101)

has

allowed

immunologists to dissect the response of the T-cell immune system to
antigenic challenge.

Activation of the immature cytotoxic lymphocytes

(CTL) to their mature form requires two signals (62,101) corresponding
to

the

competence

and

progression

states

described by Leof and associates (59).

of

the

fibroblast

model

Signal one, antigen binding to a

clonally specific receptor, renders the cells receptive to the second,
or inductive,

signal provided by IL-2.

The binding of IL-2 to

nonclonally- distributed receptor (IL-2-R),

expressed on sensitive T-

cells, triggers clonal proliferation, the immune response.
Smith (62)

have utilized this two-step

its

Cantrell and

induction to demonstrate

competent progressive model of the cell cycle with lymphocytes.

the
The

competent state is achieved when antigen (anti-T3-Ab), in the presence
of IL-1

combines with the antigen receptor (T3).

IL-2-R appear on the

cell membranes but the cells fail to move into the progressive state.
Addition of IL-2

to the cultures

is required for movement

into

the

progressive state and lymphoproliferation to occur.
As with the

fibroblast model proto-oncogene expression correlates

with competence and progression of the lymphocyte.

Increased expression
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of the c-myc oncogene has been documented in lymphocytes when they are
stimulated with lectin mitogen (Con A)

Stern and Smith

(68,163,164).

(78) have recently demonstrated activation of specific proto-oncogenes
for the competent and progressive states of the stimulated lymphocytes.
Competence, antigenic interaction with lymphocytes,

is associated with

an immediate increase in c-fos gene transcription, maximum at 30 minutes
(164), and a 10-fold increase in c-myc gene transcription at one hour
(78).

Progression,

when IL-2 binds

to the IL-2-R expressed on the

competent cell, is associated with a four to six fold increase in c-myb
gene expression by five hours after IL-2 stimulation (78,79).

Statement of Research

In the papers that follow we will present evidence for four growth
regulatory factors produced by the H238 tumor cell line.

Three of these

factors are similar to previously described positive growth factors.
The

fourth

factor

is

a negative

regulator

of

lymphocyte

function.

Evidence will be presented to support the theory that these factors not
only help to maintain the tumor but also allow it to curcumvent the host
defenses.
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Abstract
THE ISOLATION AND CHARACTERIZATION OF GROWTH REGULATORY FACTORS PRODUCED
H238

BY A HERPES SIMPLEX VIRUS TYPE 2 TRANSFORMED MOUSE TUMOR CELL LINE

by
Robert B. Stagg

The

production

transformed

mouse

conditioned medium
activity

for

DNA

of

growth

tumor

regulatory

cell

(H238-CM)
synthesis

line,

factors

was

by

H238,

investigated.

an

HSV-2-

Serum-free

contained both mitogenic and inhibitory
in

specific

cell

types.

H238-CM

was

concentrated by ultrafiltration (1000 mol. mass cutoff) and fractionated
on

a

heparin-sepharose

affinity

chromatography

column.

Mitogenic

activity was separated into three peaks that eluted at: A) void volume,
B) 0.3-0.9 M NaCl, and C) 1.2-1.4 M NaCl.

Inhibitory activity, peak D,

bound to heparin-sepharose and was eluted at 0.4-1.0 M NaCl,
distinct from the mitogenic

activity of peak B.

it was

Peak A mitogenic

activity supported the anchorage-independent growth of EGF treated NRKc-49

cells

factor.

resembling

a

transforming

growth

factor-/?

(TGF-/3) - like

Peak B bound to lectin-coated sepharose beads and was sensitive

to trypsin, neuraminidase, and the reducing agent dithiothreitol (DTT).
These physical characteristics resemble platelet-derived growth factor
(PDGF) suggesting a (PDGF)-like factor.

Peak C activity displaced basic

fibroblast growth factor (bFGF) in an RIA specific assay.

Peak D was

inhibitory for lectin-stimulated splenocytes and allogenic MLR.
not TGF-/3 but resembles interferon (IFN) in activity.

A model for the

interaction of these factors with host will be discussed.
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It is

The Isolation and Characterization of Growth Regulatory Factors Produced
by a Herpes Simplex Virus Type 2 Transformed Mouse Tumor Cell Line, H238

INTRODUCTION

Oncogenic transformation induced by herpes simplex virus (HSV) is an
No specific viral gene or gene

exception among DNA tumor viruses.
product

has

been

linked

to

the

induction

and

maintenance

transformed state as is true for other DNA viruses (1) .

of

the

Clearly the

restriction enzyme-generated DNA fragments of the HSV genome capable of
inducing transformation (2) do not encode a complete protein (3).
has

led

to

the

proposal

of

a

"hit

and

run"

mechanism

This

for

HSV

transformation (4-6).
One restriction fragment,

the Bgl II N, mapping between

0.58 and

0.63 map units of the HSV genome contains a 737 base pair region with
insertion

sequence-like

structure

(3).

This

observation

allows

comparison with nononcogene containing retroviruses which transform by
insertion

activation

characterization of

of

growth

cellular

genes

regulatory

factors

(7).

Isolation

produced by

the

and
HSV-

transformed cells would provide evidence for activated genes of the host
and

a

possible

mechanism

for

induction

and

maintenance

of

transformation.
Autocrine stimulation of tumor cells by growth factors is believed to
be

a

significant means

by which

machinery of the cell (8) .

they escape

the normal

regulatory

Growth factors interact with cells through

their specific receptors activating proto-oncogenes and driving cell

27

28
proliferation (9,10).

Growth factors are not as a rule the products of

transforming genes, but two known exceptions are: the product of the vsis oncogene which has homology to

the /?-chain of platelet-derived

growth factor -(11); and the product of the int-2 transforming gene of
Kaposi's sarcoma which has homology to fibroblastic growth factor (12).
This

study was

undertaken

to

characterize

the

growth

factors produced by an HSV-2 transformed cell line, H238.

regulatory
We report

four factors secreted into the tissue culture medium under serum free
conditions.
fourth is

Three of these factors are positive growth factors and the
an inhibitor of cell proliferation.

present paper will be on the
factors.

The emphasis

identification of the positive

in the
growth

A more detailed description of the inhibitory factor's action

on splenocytes will appear separately.
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MATERIALS AND METHODS

Cell Lines.

The H238 cell line (13) received from Dr. A. L. Boyd is a

BALB/c embryonic fibroblast cell line that has been transformed in vitro
by a UV-inactivated herpes simplex virus Type 2 (Savage strain),

Tumor

induction in the synergistic BALB/c host is 100% when 1 x 10^ cells are
injected

subcutaneously

into

the

right

thigh

(13,14).

Cells

were

routinely maintained in Dulbecco's modified Eagle's medium (DMEM; GIBCO,
Grand Island, NY) supplemented with 10% fetal calf serum (FCS;

Irvine

Scientific, Irvine, CA) 2 mM glutamine and 50 ug/ml gentamycin at 37°C
and 5% CO 2-

H238

Conditioned Medium

To collect serum-free

(CM) .

cultures, two-thirds to three-fourths confluent in 75 cm

CM,
o

H238

cell

tissue culture

flasks, were first washed three times with serum-free DMEM, then fresh
serum-free DMEM was added.

Cultures were incubated at 37°C for one to

two hours at which time medium was again replaced with fresh serum-free
DMEM supplemented with glutamine and gentamycin.
every

48

hours

Collection was

for

one

to

two

weeks

H238-CM was collected

depending

on

the

culture.

terminated if the cell sheet sluffed off the culture

flask plastic surface; medium from cultures with floating cell sheets
was discarded.

CM was clarified by centrifugation, pooled and frozen at

-70°C until use.

Concentration,

approximately 10 fold,

were performed using an Amicon ultrafiltration system.

and dialysis
The original

ultrafiltration was done with a YM-2 membrane (1000 mol.wt. cutoff) and
dialyzed against phosphate buffered saline (PBS,

150 mM NaCl, 18.3 mM
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Na2HPO^, 1.7 mM NaH2POZf); subsequently they were concentrated with a YM5 membrane (5000 mol.wt. cutoff) and dialyzed against 50 mM NaCl, 10 mM
Final protein concentration was from 0.5-1.5 mg/ml as

Tris (pH 7.4).

determined by Bradford dye binding (15).

FPLC Affinity Chromatography.

H238-CM in 50 mM NaCl (0.2-1 mg/ml;

10

ml) was applied to a FPLC Heparin-Sepharose CL-6B affinity column (1.5 x
9 cm; Pharmacia, Piscataway, NJ).

The column was equilibrated with 100
Bound protein

mM NaCl, 10 mM Tris (pH 7.4) at a flow rate of 1 ml/min.

Fractions comprising the

was eluted with a 0.1 to 3.0 M NaCl gradient.
major growth-inducing activity were pooled.

*5

The mitogenic activities of

[H]-Thymidine (TdR) Incorporation Assay.

H238-CM and the Heparin-Sepharose fractions of it were assayed by a two
"3

hour incorporation of [ H]-TdR (ICN, Irvine, CA) into embryonic chick
calvarial cells after an 18 hour incubation with putative growth factors
This

(effectors).

et al.

Gospodarowicz

assay
(16)

has

been

adapted

and described

from

in detail

the

method

previously

of

(17).

Briefly, embryonic chick calvarial cells are enzymatically dissociated
from 15-day embryos with 1.5 mg/ml collagenase (Worthington Type 1) in
Puck's calcium- and magnesium-free saline G.
washed with

DMEM,

hemacytometer.
serum free DMEM.

passed

through

a nylon mesh

at

and

counted with

a

Cell concentration was adjusted to 1 x 10^ cells/ml in
Cells (0.5 x 10^ cells/well in 0.5 ml final volume)

were plated in 48 well culture plates
hours

The dissociated cells were

37°C before

(Costar)

CM or heparin-sepharose

and incubated for 24
fractions

were

added.
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Proliferation was assayed by [^H]-TdR pulse (2 /iCi/well, SA 50 Ci/mM),
labeling which

was

terminated by

washing

cultures

with

phosphate-

Trichloroacetic acid (TCA)-

buffered saline and freezing the plates.

precipitable radioactivity was determined by swabbing the wells with
Radioactivity was

cotton-tipped applicators moistened with 12.5% TCA.
quantitated by

liquid

scintillation

counting

of

the

washed

swabs.

Treated groups

Assays consisted of 6 replicate culture wells/group.

were compared to positive controls treated with 1% FCS and untreated
controls

which

Statistical

received

analysis

of

50
the

jug/ml

bovine

difference

serum

between

(BSA).

albumin

groups

was

done

by

Student's T-test.

Transforming Growth Factor fl (TGF-yS) Assay.

TGF-/9 activity was assayed

by the stimulation of NRK (Clone 49F) cell colony formation in soft agar
culture

as

described by DeLarco

suspended (2 x 10^ cells/ml)
equal volumes
effectors.

(18) .

NRK

cells

were

in 0.3% agar in a medium consisting of

of DMEM and Ham's
Effectors

and Todaro

consisted

F12

supplemented with

10%

of

test

and

epidermal growth factor (EGF) at 1 ng/ml.

sample

with

FCS

and

without

One ml of cell suspension was

added as a top-layer to 6-well culture plates

(Falcon) over a 1.0 ml

bottom layer of 0.5% agar in the same medium without effectors,

After

ten days incubation at 37°C colonies of greater than 20 cells ( >75 /zm
diameter) were counted in duplicate wells without fixation or staining
using an inverted microscope with 350X magnification and an ocular grid.
The colonies counted were similar in size and morphology to the large
colonies described by Roberts et al. (19).
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Fibroblastic

Growth

Factor

(FGF)

Radioimimine

Assay

Bovine

(RIA).

pituitary basic FGF (bFGF) purified by Heparin-Sepharose chromatography
(gift

of

Dr.

D.

Gospodarowicz)

was

( 125 I,

radioiodinated

Amersham,
Antiserum

Arlington Heights, IL) with lodogen (Pierce, Rockport, IL) .

to bFGF (residues 1-24) was a rabbit polyclonal serum (gift of Dr. A.
Baird).

Assay buffer consisted of 50 mM Na phosphate (pH 7.2), 0.1% BSA

and 0.05% NaN^.
100 /il effectors

Reaction mixture (500 jul) consisted of 200 /il buffer,
(standards or competitors) ,

100 /il antiserum (final

dilution 1:2 x 10^) and 100 /il ^^I-labeled bFGF (25,000 cpm total).
Mixtures were incubated at 4°C for 24 hours.

Separation of the bound

and

precipitation

free

labeled bFGF

was

accomplished

by

of

bound

complexes when 100 /il of a goat anti-rabbit gamma-globulin mixture and
200 ul of a non-immune rabbit serum utilized as a carrier (2% in buffer)
were

added

to

the

Reaction

reaction mixture.

mixture

was

again

incubated at 4°C for 24 hours and then centrifuged at 500 x g for 20
minutes.

Supernatants were decanted and the pellet counted in a gamma

counter.

Typically, this RIA could measure from 0.6 to 20 ng/ml bFGF

with

displacement

50%

occurring

at

approximately

3

ng/ml

and

90%

displacement with about 20 ng/ml.

Interassay variation was 10% with

nonspecific binding of 10%

total

of the

counts

precipitated.

Total

specific counts bound in the absence of competitor was 4000 cpm's. The
closely related molecule, acidic FGF, did not displace at doses up to

250 ng/ml.
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RESULTS

Detection of Growth Factor Activity.

Serum-free conditioned medium (CM)

from H238 tissue cultures was concentrated approximately ten fold with a
Amicon

ultrafiltration

system

utilizing

a

1000

mol.

wt.

cutoff.

Mitogenic activity was detected in the concentrated CM when tested at
3
protein concentrations of 3 and 10 /xg/ml in a [ H]-TdR incorporation
assay (Table 1) .
sepharose

was

system.

A

The binding of the mitogenic activity to heparin-

determined

utilizing

a

gradient

of

concentration

Pharmacia

separated into 3 peaks,
this

laboratory's

chromatography

0.1-3.0 M NaCl

elution, and 2 ml fractions were collected.
3
in the [ H]-TdR incorporation assay.

FPLC

was

used

for

These fractions were tested

Mitogenic activity was found to be

designated A, B

and C (Fig.

1) .

Because of

interest in inhibitors of lymphocyte proliferation

(20) the fractions were tested in a lectin-induced lymphoproliferation
assay.

An inhibitory activity was detected eluting with the middle peak

B of the mitogenic activity and designated peak D (Fig. 2).

Characterization of Peak A.
independent

cultures

transforming

growth

in

factor

Because H238 cells can grow as anchoragesoft

agar

activity.

(13,14)
CM,

the
with

CM was
and

tested

without

for
acid

treatment, was able to support anchorage-independent growth but only in
the presence of EGF indicative of TGF-/3 like activity (Table 2).

Peak A

which did not bind to heparin-sepharose was subsequently tested for TGF
activity and similar results were found (Table 2).
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Characterization of Peak B.
between 0.3-0.8 M NaCl.

Peak B eluted from the heparin-sepharose
It was

neuraminadase, and DTT (Table 3).

found to be

sensitive

to

trypsin,

It bound to lectin-coated sepharose

beads and was stable at mild acidic conditions (pH 6.4) (170 vs 166 % of
control).

Characterization of Peak C.

Peak C eluted from the heparin-sepharose

between 1.1-1.4 M NaCl of the gradient.

When dialyzed against 0.05 M

acetic acid (pH 6.4) all mitogenic activity was lost.

Because FGF is

the only growth factor known to bind this tightly to heparin-sepharose,
the CM and heparin-sepharose fractions were
(Table 4).

tested by an RIA assay

CM displaced labeled-FGF in a dose dependent manner.

FGF-

like activity from tumor CM was found to be approximately 7 ng/mg of
total CM protein which was consistent for several separate collections
of CM.

Characterization of Peak D.

Coeluting with peak B (0.4-0.9 M NaCl) was

a growth inhibitor of lymphocyte proliferation.

This activity was found

to inhibit a variety of in vitro immunological function assays (Table
5).
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Table 1 Production of mitogenic activity by
H238 tumor cell line

1 x 10 cells were plated in 0.5 ml of serum free medium on 48 well
tissue culture plates. After 24 hours effectors were added.
24 hours
later incorporation of [3H]-TdR into the acid-precipitable fraction was
assayed. Values represent the mean ± SE of six wells.

Control

% of
Control

191.8 ±

100.0

41.7

1784.3 ± 304.2

1% FCS
H238 CM

CPM [3H]-TdR
incorporation

3 /zg/ml
10 ng/ml

a P < 0.001

553.8 ±

930.2 ± 158

44.2

288.7 ± 23a

727.8 ± 153.7

379.4 ± 80a
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Table 2 TGF activity
NRK colony formation in soft agar

2000 NRK-C-49F cells per plate in 0.3% agar medium containing 10% FCS.
Effectors were added at the concentrations indicated in the presence or
absence of 1 ng/ml EGF. Colonies > 75 jum were scored. Values represent
the mean of duplicate wells minus the EGF background.
Colonies per well
EGF (1 ng/ml)
With

Without

0.2 ng/ml

0

268

1.0 ng/ml

0

450

20 Mg/ml

0

200

H238 CM
20 /ig/ml
(acid treated)
Hep-Seph Fraction 9
(0.1 ml in 2 ml)

0

206

0

465

Effectors

TGF-/3

H238 CM
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Table 3 Stability of peak B growth factor to treatment
with reducing agents, enzymes, and lectins bound to beads

Peak B effector was treated with reducing agent and enzyme for 180
minutes at which time
medium containing 10%
FCS was
added.
Incorporation of [3H]-TdR into acid-precipitable fraction was assayed.
Values represent the mean ± SE of six wells
■3

[ H]-TdR incorporation (% of control)

Treatment

Buffer
Control

Peak B

None

100

226 ± 36

DTT

123 ± 21

143 ± 11

Trypsin

119 ± 18

117 ± 22

Neuraminadase

106 ± 20

128 ± 18

Lentil lectin

130 ± 21

(unbound)
166 ± 14
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Table 4 RIA for FGF activity

100 pil of CM or heparin-sepharose fraction 21 were tested in a
competitive binding assay with 125I-labeled bFGF against a rabbit
polyclonal bFGF antiserum.
Separation of bound and free labeled bFGF
was accomplished by precipation with a goat anti-rabbit gamma-globulin.
Assay could measure from 0.6 to 20 ng/ml.

Additive

FGF

H238 CM

Cone.
added

%B/B0

Cone.
ng/ml

13.9

ng/ml

25.0

5.3

ng/ml

40.0

1.7

ng/ml

60.0

1.9

mg/ml

25.5

13.4

0.95 mg/ml

34.1

7.5

0.48 mg/ml

48.6

3.2

40.2

6.5

Hep-Seph. fraction
2.0 M NaCl
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Table 5 Peak D growth inhibitory activity
against spleen cells
For lymphoproliferation 2 x 10^ spleen cells in 0.2 ml of medium were
induced with 2.5 pg/ml of Con A.
Two days later the incorporation of
For allogenic mixed
[3H]-TdR was assayed after a 5 hour pulse.
lymphocyte reaction 3 x 105 effector cells and 3 x 105 mitomycin C
Five days
treated stimulating cells were plated in 0.2 ml of medium,
later the incorporation of [3H]-TdR was assayed after a 12 hour pulse.
Values represent the mean ± SE of triplicate wells.
-a

[ H]-TdR incorporation
dpm

Assay

%
Inhibition

I. Lymphoproliferation
Treatment
107424 ± 11747

Con A
Con A + H238 CM

32488 ± 11607a

69.8a

II. Mixed lymphocyte reaction
40434 ± 8203

Control
H238 CM

a P < 0.0001
b P < 0.0003

220 pg/ml

2042 ± 106b

94.9b

110 pg/ml

7631 ± 1812a

81.la
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Serum-free H238-CM (10 mg
Fig. 1. Affinity chromatography of H238-CM.
total protein) concentrated 20 fold by ultrafiltration was passed
through an FPLC column of heparin-sepharose equilibrated with 10 mM
Two
Column gradient was from 0.1-3.0 M NaCl.
Tris, 100 mM NaCl.
milliliter fractions were collected at 1 ml/min. Mitogenic activity was
assayed by culturing chicken calvarial cells (2 x 104 in 0.5 ml) in
Dulbecco' s medium containing 0.25 /xl of a 1:20 dilution of each fraction
for the last 24 hours of the assay. Proliferation was determined by the
Values
incorporation of [3H]-TdR into the acid-precipitable fraction,
represent the mean % of control of six experiments.
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Fraction Number
Serum-free H238-CM (10 mg
Affinity chromatography of H238-CM.
total protein) concentrated 20 fold by ultrafiltration was passed
through an FPLC column of heparin-sepharose equilibrated with 10 mM
Two
Column gradient was from 0.1-3.0 M NaCl.
Tris, lOOmM NaCl.
milliliter fractions were collected at 1 ml/min.
Spleen cell inhibitory
activity was assayed by culturing splenocytes (2 x 10 in 0.2 ml) for 40
hours with Con A (2.5 mg/ml) in RPMI 1640 medium containing 0.1 ml of a
1:10 dilution of each fraction.
Proliferation was determined by [ H]TdR incorporation.
Values represent the mean % inhibition of three
experiments.

Fig. 2

42
DISCUSSION

The determination of a mechanism for transformation by herpes simplex
virus Type 2 has been difficult to elucidate.

In an attempt to develop

a relationship between HSV-2 transformation and the current hypothesis
regarding the loss of growth control in tumors, the autocrine hypothesis
(8), we have looked at factors produced by an HSV-2-transformed tumor
cell line, H238.

In this study we have demonstrated four biologically-

active growth regulatory factors that are produced and secreted into the
spent tissue culture medium of H238 cells.

Three of these

factors

possess activities that resemble classically described positive growth
factors for fibroblasts.

The fourth is a negative growth regulator of

an as yet undetermined lineage.
The

first

growth

factor

does

not

bind

to

heparin-sepharose

possesses transforming growth factor /?-like activity.

and

It supports the

anchorage-independent growth of EGF-treated NRK (clone 49) cells in soft
agar.
The second mitogenic activity resembles

It binds to heparin-sepharose eluting

factor (PDGF)-like protein (21).
between 0.3-0.9 M NaCl.

a platelet-derived growth

It is sensitive to trypsin, neurominadase, and

the reducing agent DTT.
The

third positive

factor

resembles

factor (bFGF)-like activity (22).

a basic

fibroblastic

growth

It binds tightly to heparin-sepharose

(eluting from 1.1-1.4 M NaCl), is sensitive to mild acid treatment (pH
6.4) and displaces bFGF in an RIA.
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The

fourth

factor

is

a negative

regulator

that

inhibits

lectin-

It binds to heparin-sepharose, and

stimulated lymphocyte proliferation.

elutes from it in the 0.3-0.9 M NaCl gradient region.
The production of TGF-^ and PDGF-like activities from a fibroblastic
tumor cell line is not an unexpected finding and probably not a unique
Production of PDGF like activity has

event for HSV-2 transformation.

been reported in a wide variety of transformed and tumor cells (23).

Leof and associates have demonstrated

another fibroblast line, ARK-2B
the

induction

homologous

to

of

a

PDGF

c-sis

by

In

activity

TGF-/3

and

the
This

(24) .

transcription
may

represent

of
a

mRNA
self-

perpetuating deregulated loop of transformed fibroblasts where TGF-/3
induces

PDGF which

in turn induces

TGF-/3 as part of

its

mitogenic

activity.
The demonstration of a negative

growth regulator with

inhibitory

activity for normal fibroblasts and lymphocytes may serve a dual purpose
in the overall mechanism of tumor progression.

First, the escape of the

transformed cell from negative regulation would upset the homeostatic
balance

observed

ineffectiveness

of

in
the

normal

cells

negative

(25).

regulation

Quite
would

possibly
allow

for

the
the

uncontrolled synthesis of the positive regulators seen in this HSV-2
transformed cell line.
and/or

PDGF

Second,

the

could

Loss of the negative regulation of either TGF-/?

account

inhibition of

for

the

apparent

deregulation

lymphocyte proliferation by a

observed.
tumor

cell

product would interfere with the hosts ability to mount an effective
immune

response.

It

would

allow

for

the

infiltration

into

the

developing tumor of competent immune cells possessing clonally-specific
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receptors

for

the

expansion

typical

transformed
of

a

cell

successful

but

would

immune

inhibit

response.

the

clonal

Rosenberg

and

coworkers (26) have demonstrated tumor infiltrating lymphocytes that are
capable of successfully combatting a tumor upon in vitro expansion.
The demonstration of a factor that resembles a bFGF like activity is
It has been reported for other tumor cell lines

somewhat controversial.

but when the gene for bFGF was cloned it was found not to possess a
signal peptide and therefore was believed to be cell-associated (27) .

A

determination of any possible causal relationship of bFGF secretion and
herpes virus -induced transformation needs to be followed up in light of
the transforming potential of FGF.
Kaposi's

sarcoma where

the

int-2

In particular,
gene

has

been

this is true with
implicated

as

the

transforming gene of the cells (12) and in light of the isolation of a
novel

herpes

virus

found

in

several

individuals

suffering

the

lymphoproliferative disorders seen in AIDS-related complex disease (28).
Further

studies

with

other

herpes

virus-transformed

cells

to

determine causal relationships to deregulated growth regulatory factor
production may help to determine the problematic mechanism of herpes
virus transformation.
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Abstract
THE ISOLATION AND CHARACTERIZATION OF A SPLENOCYTE GROWTH INHIBITORY
FACTOR H238-GI PRODUCED BY A HERPES SIMPLEX VIRUS TYPE 2 TRANSFORMED
MOUSE TUMOR CELL LINE, H238
by
Robert B. Stagg

Previous reports have indicated that mice bearing tumors from the H238
3
Lymphoproliferation, [ H]cell line have an impaired immune response.
thymidine (TdR)
medium

incorporation,

(H238-CM)

from H238

is inhibited by serum-free conditioned
H238-CM was

cultures.

concentrated by

ultrafiltration (1000 mol. mass cutoff) and fractionated on a heparinsepharose affinity chromatography column.

A trypsin-sensitive growth
H238-GI inhibited a

inhibitor (H238-GI) was eluted at 0.4-1.0 M NaCl.
variety

of

proliferation,

splenocyte

function

assays:

lectin-induced

allogenic mixed lymphocyte reaction,

IL-2 by lectin-stimulated splenocytes.

splenocyte

and production of

In a dose-response study (0.12-

0.48 /ig/ml) [^Hj-TdR incorporation was inhibited (29-40 %, p < 0.004) by
H238-GI, but [H]-uridine and [H]-leucine incorporation was unchanged.
Pretreatment of spleen cells with lectin + H238-GI, followed by removal
of the factor, had no lasting effect on the proliferation assay, but
when

H238-GI

was

added

back

at

19

hours

posttreatment,

proliferation was again inhibited (32.6 %, p < 0.006).
need for the continued presence of H238-GI for

the

cell

This indicated a

inhibition to occur.

Treatment of IL-2 dependent CTLL-1 cells with H238-GI showed a marginal
inhibition (14.3 % at 250 units of IL-2. p < 0.003), but when cells were
49

denied IL-2 for 24 hours, then given IL-2 in the presence of H238-GI
inhibition
transition.

was

increased,

indicating

a

possible

block

in

Gq/G-^

To determine a possible site of H238-GI action within the

cell cycle the c-myc proto-oncogene expression was examined.

H238-GI

inhibited c-myc transcription by 30 % at 3 hours post-lectin addition,
indicating possible arrest of the splenocyte proliferation cycle in Gq
by H238-GI.
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THE ISOLATION AND CHARACTERIZATION OF A SPLENOCYTE GROWTH INHIBITORY
FACTOR H238-GI PRODUCED BY A HERPES SIMPLEX VIRUS TYPE 2 TRANSFORMED
MOUSE TUMOR CELL LINE, H238

Lymphocyte proliferation in response to antigenic challenge is the
cornerstone of the immune system's ability to combat invasion by foreign
agents (1,2) .

Factors which would interfere with this clonal expansion

would seriously impair the animal's ability to fight off infection and
tumor growth.

A variety of factors isolated from the serum of tumor-

bearing animals (3-7), ascities fluid (8,9)

and the tumor itself (10These

18) have been demonstrated to inhibit immune function assays.
assays usually are

in vitro proliferation assays,

specific

examples

being the mixed lymphocyte reaction and lectin-mitogen stimulation, and
indicate factors that inhibit the clonal expansion of the lymphocyte.
Lymphocyte proliferation is a two stage event (19,20),

similar in

concept to the competence-progression model for fibroblasts proposed by
Pledger and associates (21) .
tight

control

of

each

The unique aspect of this model is the

stage

by

protein

growth

factors.

In

the

lymphocyte model, competence is established by the interaction of cells
with antigen and IL-1 (22) which induces competence factor genes
26),

IL-2 production (22,27,28)

lymphocyte (29,30).

(23-

and IL-2 receptor expression in the

Progression is solely under the control of IL-2

acting through its receptor to drive the cell through its cycle (29) .
Specific proto-oncogene expression is associated with both states.

The

c-myc gene is a competence factor gene, expressed upon mitogen challenge
51
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of lymphocytes (23-26).

The c-myb gene is expressed during progression

(31,32).
We have been studying the immune response of mice to a DNA virusinduced syngeneic

tumor (33-35).

We have demonstrated a decline

in

immune function with tumor growth mediated by a suppressor macrophage
(36).

In this paper we look at a factor produced by the tumor which

inhibits a variety of immune function assays via inhibition of cell
By looking at proto-oncogene

proliferation.

induction after lectin-

mitogen stimulation we provide evidence that the factor inhibits the
establishment

of

a

competent

state

thus

allowing

mature

cells

to

recognize the tumor but inhibit the clonal expansion giving the tumor
cell another advantage.
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Materials and Methods

Animals and Cell Lines

BALB/c and C57B1/6 mice were purchased from The Jackson Laboratory(Bar Harbor, Me).

Mice used in these experiments were immunocompetent,

from 10 to 20 weeks of age.
The H238 cell line (37) received from Dr. A.

L.

Boyd is a BALB/c

embryonic fibroblast cell line that has been transformed in vitro by a
UV-inactivated herpes

simplex virus

Type

2

(Savage

strain),

Tumor

induction in the synergistic BALB/c host is 100% when 1 x 10^ cells are
injected subcutaneously into the right thigh (33).

Cells were routinely

maintained in Dulbecco's modified Eagle's medium

(DMEM;

GIBCO,

Island,

serum

(FCS;

NY)

supplemented

Scientific, Irvine

with

10%

fetal

calf

Grand
Irvine

CA) 2 mM glutamine and 50 ^g/ml gentamycin at 37°C

and 5% CO2.
CTLL-1, an interleukin-2 dependent cell line (38), received from Dr.
D. Lyle, was maintained in RPMI-1640 medium (GIBCO

Grand Island, NY)

supplemented with 10% FCS, glutamine, gentamycin, and 25% T-cell growth
factor-conditioned medium.

H238 Conditioned Medium (CM)

To collect serum-free CM, H238 cell cultures
fourths confluent in 75 cm

o

two-thirds to three-

tissue culture flasks, were first washed
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three times with serum-free DMEM, then fresh serum-free DMEM was added.
Cultures were

incubated at 37°C for one to two hours

at which time

medium was again replaced with fresh serum-free DMEM supplemented with
glutamine and gentamycin.

H238-CM was collected every 48 hours for one
Collection was terminated if the

to two weeks depending on the culture.

cell sheet sluffed off the culture flask plastic surface; medium from
CM was clarified by

cultures with floating cell sheets was discarded,

centrifugation, pooled and frozen at -70°C until use.
approximately 10

and dialysis were

fold,

(1000 mol.wt.

buffered saline (PBS,

performed using

an Amicon

The original ultrafiltration was done with a

ultrafiltration system.
YM-2 membrane

Concentration,

cutoff)

150 mM NaCl

and dialyzed against phosphate18.3 mM Na2HP04,

1.7 mM NaH2P04) ,

subsequently they were concentrated with a YM-5 membrane (5000 mol.wt.
cutoff) and dialyzed against 50 mM NaCl, 10 mM Tris (pH 7.4).

Final

protein concentration was from 0.5-1.5 mg/ml as determined by Bradford
dye binding (39).

FPLC Affinity Chromatography

H238-CM in 50 mM NaCl (0.4-1 mg/ml;
affinity

10 ml) was applied to a FPLC

Heparin-Sepharose

CL-6B

column

Piscataway, NJ).

The column was equilibrated with 100 mM NaCl, 10 mM

Tris (pH 7.4) at a flow rate of 1 ml/min.
a 0.1 to 3.0 M NaCl gradient.
activity were pooled.

(1.5

x

9

cm;

Pharmacia,

Bound protein was eluted with

Fractions comprising the major inhibitory
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Lymphoproliferation Assay

The mitogenic activity of Concavalin A (Con A) and FCS were assayed
by a five hour incorporation of [^H]- thymidine (TdR; ICN, Irvine, CA; SA
50

Ci/mM;

1

into

spleen

blast

cells

after

a

35

hour

This assay has been described in detail previously (36) .

incubation.
Briefly,

/xCi/well)

spleens from normal BALB/c mice were mechanically disrupted,

washed in ACK lysing buffer (155 mM NH^Cl; 10 mM KHCO^; 0.1 mM Na2EDTA;
pH 7.4) and the cells suspended in RPMI-1640 with 10% heat inactivated
FCS (56°C 30 Min.),

2 mM glutamine,

mercaptoethanol (2-ME).

25 /ig/ml gentamycin and 5 /iM 2-

Cells were counted with a hemacytometer and

cell density was adjusted to yield a final concentration of 1 x 10^
cells/ml for each test.
final

in

volume)

Cells were plated at 2 x 10^ cells/well (0.2 ml

96-well

culture

plates

[3H]-TdR

(Falcon).

incorporation assay consisted of two sets of triplicate wells per test,
three

received

Con A

(2.5 ^g/ral)

and three

received medium

alone.

Treated groups were compared to maximal stimulation of splenocytes by
Inhibitory activity was monitored by a decrease in Con A

Con A or FCS.

RNA and protein synthesis were determined by a five hour

mitogenesis.
pulse

of blastogenic spleen cell with

/iCi/well)
Cells

and

were

[3H]-Leucine

harvested

Gaithersburg, MD).

(SA 50

using

an

[3H]-Uridine

Ci/mM;

automated

1

(SA 50 Ci/mM;

/xCi/well)

cell

1

respectively.

harvester

(Brandel,

Radioactivity retained on filters was quantitated by

liquid scintillation counting.
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Interleukin-2 (IL-2) Production

Spleen cells at a final concentration of 1 x 10^ cells/ml, in RPMI1640 with

10%

PCS

glutamine,

gentamycin

and 2-ME were

induced

produce IL-2 by incubation with Con A (2.5 /ig/ml) for 38-40 hours.
test group consisted of 12 wells of a 96-well plate.
medium from each test

group was

collected,

to

Each

IL-2-conditioned

centrifuged,

pooled and

stored at -70°C until assayed.

IL-2 Assay

This assay has been described in detail previously (40) .

Briefly,

triplicate wells/test of 1 x 10^" CTLL-1 cells/well in a 96-well culture
plate were incubated for 18 hours with serial two-fold dilutions of ILActivity was measured by a four-

2-conditioned media from each group.

hour pulse of [ H]-TdR (1 /xCi/well) at the end of incubation.
were

harvested

scintillation

with

a

cell

harvester

Units

counting.

analysis at 50% of the IL-2

of

IL-2

standard.

and

Assays

quantitated

by

liquid

determined

by

probit

were

The standard was 1 U/ml of

recombinant IL-2 (Genzyme, Boston, MA).

Mixed Lymphocyte Reaction (MLR)

An allogenic
Erickson et al.

splenocyte
(^1).

response was

adapted

from

the method

of

Stimulation of MLR was assayed by a 20 hour
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o

incorporation of [ H]-TdR (1 /iCi/Well) into blastogenic spleen cells.
Briefly, responder BALB/c spleen cells were incubated with stimulator
C57B1/6 spleen cells for 5 days at 37°C.

Cells were plated into 96-well

culture plates at a concentration of 3 x 10^ cells/well for each cell
type

(0.2

ml

final

Stimulator

volume).

cells

were

prepared

by

incubation of 1 x 10^ cells/ml with 50 pg/ml mitomycin C for 30 min at
37°C and washed thoroughly with RPMI-1640.

Controls included responder

cells alone and stimulator cells alone.

All assays were plated in

triplicate.

Assays were harvested with a cell harvester and quantitated

by liquid scintillation counting.

RNA Isolation and Hybridization

RNA Isolation:
cells with 0.5%

Total cytoplasmic RNA was isolated by lysing spleen
(v/v) Nonidet P-40

(NP-40)

in the presence of lOmM

vanadyl ribonucleoside complexes (BRL, Gaithersburg, MD).

Lysed cells

were centrifuged to remove nuclei and organelles and extracted with
phenol chloroform.
ice-cold

ethanol

Following extraction the RNA was precipitated with
and

0.15M

sodium

acetate.

Precipitated

RNA

was

resuspended in 10 mM Tris (pH 7.4), 1 mM Na2EDTA, and 0.1% (wt/v) sodium
dodecyl sulfate (SDS).

Dot Blot preparation:

Purified RNA was prepared for analysis by

application to nitrocellulose (NC) filters (Schleicher & Schuell, Keene,
NH) by a "Dot Blot" method proscribed by the manufacturer.

Briefly, RNA

in 6X SSC buffer (IX is 150 mM NaCl, 15 mM sodium citrate) and 20% (v/v)
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Serial two

formaldehyde was denatured by heating at 60°C for 15 min.

fold dilutions (5, 2.5, 1.25 /ig total RNA) in ice-cold 20X SSC buffer
were made and then applied to NC filters using a "Minifold" Dot Blot
filtration manifold (Schleicher & Schuell, Keene, NH).

Filters were air

dried and then baked under vacuum for two hours at 80°C.

Hybridization:

NC filters were prehybridized in sealed plastic bags

for four hours at 42°C in a reaction buffer of 50% formamide, 5X SSPE
(IX SSPE

is

Denhardt's

150 mM NaCl,
solution

Polyvinylpyrrolidone
salmon sperm DNA.

(

10 mM Na^PO^^O and
SOX

is

1%

360,000 mol.wt.),

Ficoll
0.5%

(v/v)

1 mM Na2EDTA) ,
400,

1%

SDS

BSA,

5X
1%

and 100 /ig/ml

Hybridization was carried out in the same buffer

containing additions of 10% (wt/v) dextran sulfate (500,000 mol.wt.) and
2 x 10^ cpm/ml [ ^P] - labeled CDNA probe.

The cDNA probe was a 1800 base

pair Clal-Eco R1 restriction fragment of the human c-myc third exon
(Oncor, Gaithersburg, MD) and labelled with [32P]-dCTP (3000 Ci/mM; ICN,
Irvine, CA) to a specific activity of 1 x 10 8 cpm//jg DNA.
performed by

the

random

priming method

of

Feinberg

Labeling was

and Vogelstein

(Anal.Biochem 137:266 '84) utilizing an Oligolabelling Kit (Pharmacia,
Piscataway, NJ).

Hybridization was carried out at 42°C for 48 hours.

At the end of hybridization NC filters were washed two times in 2X SSC
and 0.1% SDS at room tempature for 30 min.
0.1% SDS at 50°C for 30 min.

Final wash was 0.IX SSC and

Filters were exposed to Kodak XAR-OMAT

film with Dupont Cronex Quanta III intensifing screens at -70°C for 4
days.
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Results

The inhibition of the lectin-induced stimulation of splenocytes by
the conditioned medium of an HSV-2-transformed tumor cell line, H238
To aid in a

has been previously reported from this laboratory (42) .

further study of this activity, serum-free conditioned medium (CM) was
collected from cultures of the H238 cells.

The H238-CM was concentrated

approximately 10-15 fold by ultrafiltration, using a 1000 mol. wt. cut
off membrane,

and

dialyzed

against

The

PBS.

concentrated H238-CM

possessed a trypsin-sensitive factor that showed an increased inhibitory
activity when assayed in the lectin mitogen stimulation assay using PHA
and Con A (Table 1).
To

determine

whether

the

on

the

splenocytes or just inhibiting their lectin-induced stimulation,

the

growth inhibitory factor

(H238-GI)

lymphocyte response (MLR).
pronounced (Table 2).

inhibitory

factor

was

acting

was tested in an allogenic mixed

The inhibition of the MLR by the H238-GI was

Further, the H238-GI's effect on IL-2 production
The spleen cells treated with H238-GI

of the splenocytes was examined.

were markedly inhibited in their IL-2 response to

lectin-stimulation

(Table 3).
While the growth factor activity produced by the H238 cells during
these

experiments

was

being

examined,

it

was

inhibitory activity bound to heparin-sepharose.

observed

that

the

An aliquot containing

10 mg total H238-CM protein was applied to an FPLC heparin-sepharose
affinity

chromatography

column.

The

fractions

were

assayed

for

inhibitory activity and H238-GI was found to bind to the column and
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eluted between 0.4-1.0 M NaCl in the gradient (Fig.

The H238-GI

1).

inhibited both lectin- and serum-induced proliferation of the
cells.

spleen

Affinity chromatography-purified H238-GI was tested to determine

its effects on the lectin-induced proliferation and IL-2 production.

A

similar activity to that observed with the unfractionated CM was found
(Tables 1 & 3).
The inhibition of lectin-induced proliferation can occur at several
points in the macromolecular apparatus of the proliferating cell.

To

determine a possible site of inhibitory action, the H238-GI factor was
3
tested in a dose-response assay by pulsing the cells with either [ H]TdR,

[^H]-uridine,

or

[^H]-leucine

(Fig.

2,

Table

4).

H238-GI

specifically inhibited DNA synthesis in a dose dependent manner while
not affecting the other macromolecular processes.
In order to determine if the H238-GI could affect proliferation by a
short interaction with splenocytes, lectin-exposed cells were pretreated
with H238-GI for 3 hours,

Control

then H238-GI was removed (Fig.3).
Removal of H238-GI restored

cultures received no H238-GI.

incorporation to the levels of untreated spleen cells.

[^H]-TdR

When the H238-GI

was added back to the cultures at 19 hours post pretreatment, inhibition
was

observed.

reversible

and

This
its

indicated

continued

that

presence

the
was

inhibitory
required

activity
to

cause

was
its

antiproliferative effect.
It was of interest to determine a mechanism of action for the H238GI.

Several tumor-derived antiproliferative factors have been reported

to have immunosuppressive activities (10-18).

It is probable the H238-

GI is a normal cell product involved in the homeostatic balance of cell
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proliferation that has lost its normal inhibitory activity on the tumor
The lymphocyte proliferation model requires two steps

cell (Table 5).
for

proliferation:

1)

Gq/G-^

the

transition

induced by

antigen

and

factors such as IL-1, and 2) the G-^-S phase under the regulation of IL-2
First,

(29).
induced

a test of the ability of H238-GI to inhibit the IL-2-

proliferation

of

IL-2

the

dependent

cell

line

CTLL-1

was

A slight inhibition of the IL-2 response was observed (10747

performed.

This slight inhibition was not at the

± 1192 vs 9211 ± 801 P<0.003) .

same levels as those observed in the lectin-induced cells.

There was

concern that the inhibition was due to the small number of CTLL-1 cells
that were cycling through the early G^ phase during the 18 hour assay.
To test this possibility IL-2 was removed from the CTLL-1 cells for 18
hours

before

response

of

fresh
the

IL-2

CTLL-1

added with

was
cells

was

followed

Inhibition was more pronounced and its
entire experiment (Fig. 4)

and without H238-GI.
for

24

and

duration was

48

The
hours.

throughout

the

indicating a possible action during the G^

phase.
The

c-myc

proto-oncogene

stimulated lymphocytes

is

an

early

response

gene

in

lectin-

(23-26) and is indicative of Gq/G-^ transition.

It has also been implicated in the activation of DNA polymerase.

In a

test to determine the possible relationship between H238-GI inhibition
and c-myc induction,
kinetic

cytoplasmic RNA was isolated in a lectin-induced

study with and without H238-GI.

inhibited

30%

at

3

hours

(Fig.

5)

c-myc gene expression was

corresponding

to

the

level

of

3
inhibition of [ H]-TdR incorporation observed in the proliferation assay
for this concentration of protein (Table 5).
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TABLE I
Inhibition of lectin-induced splenocyte proliferation
by H238-GI
[^H]-TdR incorporation
PHA

186493b

Control
H238 CM

Con A

Con A
Trypsin3

86755

288 mg/ml

59732 (68)c

5177 (94)

144 mg/ml

68309 (63)

20098 (77)

62405 (28)

72 mg/ml

111093 (40)

24862 (71)

65676 (24)

Control

ND

1:40
Hep-Seph
fraction 20
1:80

ND

38217 (66)

ND

45097 (60)

ND

65469 (42)

1:160

10514 (88)

113764

a CM was treated with trypsin for 3 hours before
addition of media and 10% FCS.
b Values represent mean dpms of triplicate wells
c % inhibited (control dpm - test dpm)/control dpm
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TABLE II
Effect of H238-GI on allogenic mixed lymphocyte cultures3
[^H]-TdR incorporation
Expt. 2

Expt. 1

Control

40434 ± 8203b

H238 CM

2042 ± 106

8996 ± 2857
(94.9) c, d

4778 ± 1163 (47)e

a 3 x 105 effector and mitomycin C target cells were
incubated for 5 days with a 5 hour pulse label.
b Values represent mean dpms of quadruplet cultures.
c % inhibited (normal dpm - test dpm)/control dpm x 100.
d P < 0.0003
e P < 0.02
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TABLE III
Effect of H238-GI on IL-2 production by lectin-induced splenocytes
Units IL-2
Addition

Con A
Con A + H238 GI
Con A + Hep-Seph.
fraction 20

a Probit analysis
b % inhibition

Expt. 1

Expt. 2

Expt.3

12.8a

9.5

7.6

6.4

(50)b

8.5

(10)b
2.8

(63)b
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TABLE IV
H238-GI effect on splenocyte macromolecular synthesis

3
[ H] incorporation
TdR

Treatment

uridine

leucine

Control

203679a

109454

7290

0.48 mg/ml
Hep-Seph
fraction 20
0.24 mg/ml

121431 (40) b, c

119692

6127f

145586 (28)d

112261

6313

144610 (29)e

103524

6645

0.12 mg/ml
a
k
c
d
e
f

Values represent mean dpms of triplicate cultures
% inhibition
P < 0.001
P < 0.003
P < 0.004
P < 0.07
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TABLE V
Effect of H238-GI on H238 cells
[ 3 H]-TdR incorporation
Expt. la

Expt. 2b

1% FCS

2% FCS

10% FCS

Buffer

4983 ± 715c

4093 ± 407

19688 ± 5895

H238-CM

4318 ± 844

4326 ± 1366

14665 ± 3995d

Addition

a 2 x 10A cells were cultured for 24 hours in 0.5 ml serumfree before effectors were added. 18 hours later cultures
were pulsed for 5 hours.
b 2 x 104 cells were cultured for 24 hours in 0.5 ml media
with 0.5% serum before effectors were added. 18 hours
later cultures were pulsed for 5 hours.
c Values represent mean dpms ± SE of six cultures
d not statistically significant
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Fraction Number
Serum-free H238-CM (10
Affinity chromatography of H238-CM.
Figure 1.
mg total protein) concentrated 20 fold by ultrafiltration was passed
through an FPLC column of heparin-sepharose equilibrated with 10 mM
Two
Column gradient was from 0.1-3.0 M NaCl.
Tris, 100 mM NaCl.
Spleen
cell
inhibitory
milliliter fractions were collected at 1 ml/min.
activity was assayed by culturing splenocytes (2 x 105 in 0.2 ml) for 40
hours with Con A (2.5 pg/ml) in RPMI 1640 medium containing 0.1 ml of a
1:10 dilution of each fraction.
Proliferation was determined by [3H]TdR incorporation.
Values represent the mean % inhibition of three
experiments.
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Figure 2. The effect of H238-GI on the macromolecular biosynthesis of
lectin-stimulated splenocytes.
In panel A the inhibitory activity of
H238-GI for Con A-induced (2.5 /ig/ml) spleen cells (2 x 105 in 0.2 ml)
Proliferation of
was tested in a dose-response assay (0.12-0.48 /zg/ml).
In Panel B RNA
DNA was measured by the incorporation [3H]-TdR.
transcription was measured by [3H]-uridine incorporation.
In panel C an
H238-GI dose-response assay for protein synthesis was measured by [ H]Values represent the mean ± SD of the total
leucine incorporation,
dpm's of three experiments.
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Figure 3. The effect of H238-GI pretreatment on lectin-stimulated
In panel A splenocytes (2 x 10^ in 0.2 ml)
splenocyte blastogenesis.
were cultured for 3 hours with Con A (2.5 ng/ml final concentration) in
the presence (open box) or absence (hatched box) of H238-GI (0.48 /xg/ml)
at which time effectors were removed.
The resulting proliferation was
measured by [3H]-TdR incorporation at 48 hours post-treatment.
At 19
hours post-treatment one set of cultures received additional H238-GI
(0.48 /xg/ml) (cross-hatched box).
In panel B splenocytes were again
pretreated for 3 hours with Con A (2.5 /xg/ml) in the presence (open box)
or absence (hatched box) of H238-GI (0.48 /xg/ml).
At 19 hours post
treatment one set of cultures received additional H238-GI (0.48 /xg/ml)
(cross-hatched box).
Values represent the mean ± SD of the total dpm's
of three experiments.

70

ro

14-

a

B

o

x 12w
c
o
u

E 10-

CL
XI

c
o

8-

O

D

o

6-

Q_

a;

o
o
c
ji

*

s
N
N
ssS

CL

42-

s
ss

N

S
X

X

r>

sSs
s
N

0

24

24

X

v
48

Hours
Effect of H238-GI on IL-2-induced proliferation of CTLL-1
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H238-GI (0.48 fig/ml).
Proliferation was measured at 18 hours by [3H]Total [3H]-TdR incorporation is expressed as mean %
TdR incorporation.
Sd of three experiments. Panel B, CTLL-1 cells (1 x 10A in 0.2 ml) were
deprived of IL-2 for 24 hours before addition of effectors. At 24 hours
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Cultures were terminated at 20
(hatched box) of H238-GI (0.48 /xg/ml).
Total [3H]-TdR incorporation is expressed as
and 40 hours thereafter.
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Figure 4.
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Figure 5. Effect of H238-GI on lectin-induced c-myc proto-oncogene
expression.
Splenocytes (1 x 107 in 10 ml) were cultured with Con A
(2.5 /ig/ml) in the presence (0) or absence (0) of H238-GI (0.19 /zg/ml) .
Cytoplasmic RNA from cultures was extracted and measured at the
indicated times by dot blot analysis using a c-myc DNA probe.
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DISCUSSION

In

this

study

we

report

the

immune

inhibitory

activity

of

a

nondialyzable factor (H238-GI) produced by the H238 HSV-2-transformed
It strikingly inhibits

mouse embryonic fibroblast tumor cell line.
splenocyte

proliferation

competence,

assays

lectin-induced

to

designed

stimulation,

measure

allogenic

production of lectin-stimulated splenocytes.

MLR,

immunologic
and

IL-2

It also inhibits the IL-2

dependent proliferation of CTLL-1 cells but at a fraction of the level
The inhibition of splenocytes is

of inhibition seen in Gq splenocytes.

reversible and can exert its inhibitory effect when present for only the
last 24 hours of culture.

It acts in a dose-dependent manner inhibiting

3
DNA synthesis, as measured by [ H]-TdR incorporation, while having no
quantitative

effect

on

the

RNA

and

protein

Qualitatively,

stimulated splenocytes.

synthesis

of

in a kinetic study H238 was

found to inhibit the expression of the c-myc proto-oncogene.
gene

is

an

stimulation

early
of

response

lymphocytes

lectin-

gene

expressed

(23-26)

and has

rapidly
been

The c-myc

after

implicated

lectinto

be

associated with DNA polymerase activity (43).
The inhibition of the lectin stimulation of splenocytes is a common
characteristic of tumor cell-derived immune inhibitory factors (10-14).
In addition to the inhibition of an assay of lymphocyte function it
provides a convenient method with which to detect the antiproliferative
factors.
different

We tested two different lectins, PHA and Con A, that bind to
sugar

respectively,

to

residues,
rule

out

N-acetyl-glucosamine
selective

and mannose/galactose

inhibition of

lectin by

direct
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interaction with the lectin mitogen.

We observed no specific difference
We then

in the inhibitory activity of the H238-GI with each lectin.

tested a more specific proliferative response, allogenic MLR, and found
that this response was almost completely blocked.
more qualitative response,

We did not test for a

such as cytotoxic lymphocytes, because we

were interested in the antiproliferative activity of the H238-GI.
To rule out inhibition due to a toxic effect of the H238-GI on the
splenocytes, we measured the DNA, RNA, and protein synthesis in a dose
We observed a dose-dependent specific inhibition of DNA

response assay.

synthesis but no quantitative inhibition of RNA and protein synthesis.
This indicated that the H238-GI was not toxic and selectively inhibited
DNA synthesis.
We

looked

at

the

effect

of

H238-GI

on

the

ability

of

lectin-

stimulated splenocytes to produce IL-2.

11-2 production was inhibited

at

inhibition

a

level

that

Measurement of

correlates

with

IL-2 production has

the
a

of

direct bearing

proliferation.
on the

clonal

proliferation of the responding cells, and a decrease in its production
would

indicate

a possible

mechanism of

action.

In the

lymphocyte

proliferation model two possible sites of action for the H238-GI present
themselves, Gq/G-^ transition and G^-S progression.
G-^-S progression.

IL-2 regulates the

Based on this we looked at the H238-GI inhibition of

IL-2 stimulated proliferation utilizing an IL-2 dependent cell
CTLL-1.

line,

We found a slight inhibition that did not correlate with the

inhibition of lectin-induced proliferation.

We speculated that what was

happening in this experiment was not G^-S progression inhibition but
selective inhibition of the small percentage of cells cycling through
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To test this hypothesis we

the early G-^ phase during the 18 hour assay,
removed IL-2

from the

CTLL-1

cells

for

24 hours

in an attempt

to

synchronize the cells in the Gq state before addition of recombinant ILWe

2.

found

an

increased

inhibition

proliferation in the presence of H238-GI

of

the

IL-2-stimulated

that lasted throughout

the

period of observation indicating a probable site of action on the Gq/G-^
transition.
We decided to look for a marker of Gq/G-^ transition to determine the
effect of H238-GI on this site of the proliferation cycle.

The c-myc

proto-oncogene is a very good marker of Gq/G-^ transition that has been
associated with the regulation of DNA polymerase (43) but this is still
an unsubstantiated observation (46) .
differentially

is

that

differentiation.
lectin-induced

It is a nuclear proto-oncogene

regulated

during

proliferation

or

Its transcription is up-regulated immediately during
proliferation

and

(23-26)

differentiation of hematopoietic tissues

(44,45).

down-regulated

with

We found that the

H238-GI inhibits c-myc transcription by 30% at 3 hours which correlates
well with the inhibition of lectin-stimulated proliferation observed for
the dose of H238-GI used in this experiment.

The qualitative inhibition

of the c-myc gene transcription by the H238-GI represents a specific
site

for the

allows

for

inhibitory action within the proliferation cycle.

the

recognization by immunologically competent

inhibits their clonal proliferation.

cells

It
but

The observation of an apparent

late effect by H238-GI when added to the cultures at 19 hours post
stimulation probably represents an inhibition of further rounds of DNA
synthesis and not an action on a late G-^-S event.

The decrease in IL-2
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production

also

correlates

well

with

the

inhibition

of

c-myc

gene

IL-2 gene transcription occurs with the same kinetics as

transcription.

c-myc transcription and may be affected in a similar fashion.
Immune inhibitory factors have been reported from a variety of in
vivo

and

in

vitro

sources

characteristics similar to
esophagus

(16)

Among

(10-18).
the H238-GI;

and mouse K-1735 cells

myeloma U937 cells

(13)

these

are

several

the tumor extracts
(11)

and the CM's

of human

from human

factors inhibit mitogen stimulation, IL-2 production, and MLR.

a closer look;

These

and the HT29 human colon carcinoma.

not inhibit IL-2-dependent CTLL-2 proliferation.

with

They do

The U937 cells warrant

they produce their inhibitory factor when induced to

differentiate with phorbol esters (13).

It has also been demonstrated

that phorbol ester treatment of U937 cells causes them to differentiate
under the regulation of an autologous factor, interferon /3 (IFN /3) (44) .
IFN ft also has similar inhibitory activities for lymphoproliferative
responses that these tumor-derived factors possess (47) .

IFN P has also

been shown to inhibit c-myc transcription in PDGF treated fibroblasts
(48) and to induce Gq/G-^ arrest in hematopoietic cells associated with a
reduction in c-myc expression.
mass

seen

diversity
possible

in the
seen

The problem of pleomorphic molecular

tumor-derived

during

that these

the

tumor

inhibitory

factors

may parallel

early work

on IFN purification.

factors

related to

are

It

IFN and that

the
is
the

significance may be that the tumors that produce these factors have lost
their

ability

to

respond

as

have

the H238

production of a normal homeostatic may occur.

cells:

thus

the

over
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A factor with characteristics similar to the H238-GI would have a
significant impact on the in vivo immune response.

By inhibiting cell

proliferation without a toxic effect on the responding cells it would
allow for the infiltration into a tumor of immunologically competent
lymphocytes but would inhibit their clonal proliferation, thus allowing
the tumor to escape an effective immune response.

It would explain the

finding of immunologically effective cells within a tumor by Rosenberg
and associates (50) and why these cells are effective therapeutically
when clonally expanded in vitro and reintroduced into the host.
the

increased

therapeutic

efficacy

of biological

response

Also

modifiers

(BRM) given intralesionally as opposed to systemically could have their
effect on the cells
validity of this

inhibited by this type of factor.

factor remains

to be proven but

the

The in vivo
isolation of

several factor with similar characteristics to the H238-GI from tumors
of mesenchymal origin lends support to this type of antiproliferative
model.

If these inhibitory factors are typical of tumors of mesenchymal

tissue they would present an inviting target for therapeutic agents used
in combination with BRMs and lymphokine-activated cytotoxic cells.
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Discussion

The conditioned tissue culture medium from the H238 tumor cell line
contains nondialyzable growth regulatory factors that can be divided by
The
or negative inhibitory, activities.
3
positive factor(s) stimulated [ H]-TdR incorporation into chick embryo
their positive,

mitogenic,

calvarial

while

cells

incorporation

into

the

negative

activity

lectin-stimulated

inhibited

mouse

[3H]-TdR

the

These

splenocytes.

activities could be separated and partially purified by FPLC heparinsepharose

affinity

Upon fractionation

chromatography.

the

positive

activity was separated unto three peaks containing mitogenic activity
whereas the negative activity was confined in one peak of activity.
Characterization of
revealed
factors.

a

the

similarity
Peak A

three

to

positive

previously

possessed

the

growth

described

ability

to

regulatory

factors

polypeptide

growth

support

the

anchorage-

independent growth of EGF-treated fibroblasts which is the classical
assay for TGF-y3 (48).
(80,81).

Peak B had similar biochemical properties to PDGF

Peak C displaced bFGF in an RIA assay and binds to heparin-

sepharose with an affinity only observed with FGF-like activities (105).
The inhibitory activity, Peak D, coeluted with Peak B of the positive
It is distinct from the PDGF-like activity but its

growth factors.

lineage is as yet unknown.
interferon

(54)

relationship.
test

It possesses some similar activities to

but we have not been able

to

demonstrate

a

direct

It inhibits a variety of immunological assays designed to

immunologic

functions:

lectin-stimulation,

reaction, and production of IL-2.

82

mixed

lymphocyte
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In the following paragraphs we will discuss the interactions of these
growth regulatory factors with the tumor itself, autocrine, and with the
host, paracrine,

in an attempt to develop a plausible model for tumor
We will discuss this in light of what has been reported

establishment.

about the activities of the growth regulatory factors isolated from the
conditioned medium of the H238 tumor cell line.

Autocrine

The

autocrine

response

to

hypothesis

growth

factors

(65)
by

for
the

the
tumor

autologous
cells

is

production
an

and

intuitively

acceptable mechanism by which tumors may achieve relaxed control of the
proliferation cycle.

With the demonstration of tumor cell production of

growth factors and the presence of receptors on the same tumor cells for
the factors, this has become accepted dogma.
PDGF, bFGF, and TGF-/3 are all mitogenic for fibroblasts (80,105.112).
PDGF and bFGF act directly
inducing PDGF (112).
interferon,

as

(80,105)

while TGF-/3 acts

indirectly by

PDGF also activates a negative regulatory factor,

part of

its mitogenic

action

(165).

This

negative

activity is believed to act in the normal homeostasis of the cells'
proliferation.

PDGF and bFGF have been associated with transformation

(17,72).
For the H238 autocrine model all three growth factors are capable of
mitogenic stimulation of the tumor cells.

The demonstration of a factor

that resembles a bFGF-like activity is somewhat controversial.

It has

been reported for other tumor cell lines, but when the gene for bFGF was
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cloned, it was found not to possess a signal peptide and therefore was
A determination of any possible causal

believed to be cell-associated.

relationship of bFGF secretion and herpes virus-induced transformation
needs to be followed up in light of the transforming potential of FGF
PDGF and TGF-/3 are produced by many tumors of mesenchymal origin

(72).
(67,48)

and

may

not

transformation event.
escape

represent
Their

a

specific

target

for

continued production may

from the negative regulation of the

the

HSV-2

represent

an
The

inhibitory factor.

inhibitory factor is not active on the H238 cells; if it is similar to
interferon,

then the production of PDGF,

TGF-^,

and

the

inhibitory

factor may represent a deregulated self-perpetuating loop, where TGF-/3
induces PDGF which then induces inhibitory activity and TGF-/? and so on.
The

loss

of

the

H238

cells'

ability

to

respond

to

the

inhibitory

activity may also be a target for HSV-2 induced transformation.

Paracrine

It has long been known that transplantable tumor development requires
its interaction with host stroma if the tumor is to survive (166) .
was believed

that

this

interaction is

directed by

the

tumor

It

which

produced factor(s) that cause the chemotactic migration of fibroblasts
and vascular endothelial cells into the tumor.

These host stroma cells

are necessary for support and nutrition of the growing tumor.

With the

discovery of growth factors and that tumor cells can produce some of
these factors, it has been possible to support the earlier hypothesis.
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It induces

PDGF is a major mitogen for mesenchymal cells (15,80).
the

chemotaxis

of

(82) ,

the

production

proliferation of fibroblasts (80).

of

IGFs

by

(167) ,

and

the

It also induces the chemotaxis of

TGF-£ is a potent angiogenic factor causing the

smooth muscles (82).

chemotaxis and differentiation of vascular endothelial cells (107).
stated above TGF-fl induces PDGF production in fibroblasts (112).

As

FGF is

a major mitogen for vascular endothelial cells and potent angiogenic
factor (105).
For the H238 paracrine model these factors could interact with host
stroma to support tumor growth.
fibroblastic origin,
(IGF)

First, H238 is a transformed cell of

it probably requires insulin-like growth factors

to complete its proliferation cycle.

PDGF would stimulate the

surrounding fibroblasts to migrate into the tumor and to produce this
necessary growth factor insuring an adequate supply of IGF's for growth
of the tumor.

The migrating fibroblasts would also provide support for

the

PDGF,

tumor.

FGF,

and

IGF-/?

would

act

together

angiogenesis necessary to provide nutrition to the tumor.

to

induce

PDGF and TGF-

P would induce the migration of smooth muscle and vascular endothelial
cells.

FGF would support the necessary proliferation these vascular

endothelial cells would require to migrate.

Once they have migrated

into the tumor TGF-/? would induce them to differentiate into tubular
capillaries.

In this manner these growth factors would ensure the tumor

growth and nutrition.
The paracrine action of the inhibitory factor appears to help the
tumor cell escape the

immunological defense mechanisms.

inhibiting the proliferation of immunocompetent cells.

It acts by

In the in vivo
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environment a factor like the H238-GI would allow for the infiltration
into the tumor of immune cells capable of mounting a response but it
would

inhibit

their

proliferation.

The

inability

of

a

clonal

proliferative response by these immunocompetent cells would allow the
tumor

cells

immunologically

unobstructed

This

growth.

type

of

inhibition without toxic effect on the immune cells may be the reason
why Rosenberg and associates (128) have been able to demonstrate tumor
infiltrating lymphocytes and use them for successful therapy.

Future

This model of autocrine and paracrine interaction for tumor growth is
testable.
induced by

The possible genetic mutations in the growth factor genes
the

inactive

HSV-2

virus

needs

to

be

examined.

These

mutations may be as simple as multiplication and/or rearrangement of the
growth factor genes although this is doubtful for PDGF and TGF-/3.

The

HSV-2 insertion element could possibly act through an insertion-promoter
mechanism allowing the unregulated transcription of the growth, factor
gene.

These are relatively simple mechanisms that can be tested by

southern blot analysis.

If these are not observed, it becomes a much

more formidable task to determine the mechanism.
The possibility of an autocrine mechanism for tumor proliferation
would be strengthened by the demonstration of receptors for the specific
factors on the tumor cells.
assay using

This could be done in a receptor binding

radiolabeled purified growth

factors.

It

is

sometimes

difficult to demonstrate receptors for PDGF in transformed cells because
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the

cells

undergo

a

down-regulation

in

detectable

receptors

after

transformation (67).

This is believed to be due to the binding of the

autologous

In

PDGF.

the

case

of

the

inhibitory

factor,

two

possibilities involving the- lack of a functional receptor would need to
be looked at: one, complete lack of receptor expression, and two,

the

inability of the receptor to transmit the correct intracellular signal.
For the paracrine model the functions of PDGF,
fairly well documented.

FGF,

and TGF-/3 are

The determination of the in vivo nature of the

inhibitory factor needs to be established.
tumor secreted immunosuppressive factors

The in vivo validity of

still remains

to be proven.

But the isolation and characterization of these factors derived from in
vitro tumor cell lines is a clue to the actions of these cells in vivo. ■
If immunosuppressive factors are real they may provide a significant
site

that could be attacked successfully by the

therapeutic use of

monoclonal antibodies and biological response modifiers.
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